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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second deadliest cancer
by 2030. Previous studies showed constitutive activation of KRAS (KRASG12D) is a key
genetic driver of PDAC, accelerated by deletion of the epigenetic regulator Enhancer of
Zeste Homologue 2 (EZH2). However, contradictory findings suggest multiple roles for
EZH2. The goal of this study was to define EZH2’s contribution to early KRASG12D-driven
PDAC. I hypothesized that EZH2 restricts KRASG12D initiation of PDAC in response to
injury. To address this hypothesis, genetically modified mice with targeted deletion of the
SET domain of Ezh2 +/- KRASG12D were exposed to cerulein-induced pancreatic injury
and examined for pancreatic lesions. Histological analysis for markers of tissue damage
and inflammation showed loss of EZH2 caused no difference in the pre-neoplastic lesion
formation but did affect progression, and reduced immune cell infiltration, suggesting a
role for EZH2 in limiting early progression of KRASG12D-mediated PDAC.

Keywords: PDAC, EZH2, KRAS, pancreatitis.
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Summary for Lay Audience
In this study, I examined the role of an enzyme Enhancer of Zeste Homologue 2 (EZH2)
in the most common type of pancreatic cancer called pancreatic ductal carcinoma (PDAC)
in the presence of KRAS mutation in mice. The majority of PDAC patients bear KRAS
mutations in their genome. Our previous work showed that there are no differences in the
severity of pancreatic tissue injury whether you delete EZH2 or not. However, other studies
indicate that EZH2 deletion make the effects of KRAS mutation much stronger on the
development of PDAC. Therefore, I wanted to know if the loss of EZH2 is beneficial or
harmful for pancreatic tissue recovery from injury in the context of KRAS mutation. My
work showed that the loss of EZH2 results in more progressive pancreatic lesions, which
increase the possibility of developing into cancer. In addition, I observed more immune
cells appeared around the pancreatic lesions of mice lacking Ezh2 expression. My results
suggest that EZH2 plays an important role in the development of pancreatic cancer and
may be a potential target for anti-cancer therapy.
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CHAPTER 1: INTRODUCTION
1.1

PANCREATIC DUCTAL ADENOCARCINOMA

Pancreatic ductal adenocarcinoma (PDAC) constitutes 95% of all pancreatic cancers and
is predicted to be the second leading cause of death related to cancer in Canada by 2030
(Haeberle & Esposito, 2019). The overall five-year survival rate for PDAC is less than 9%
due to the lack of early detection methods and effective treatments (Sarantis et al., 2020).
PDAC is highly malignant and the prognosis is the poorest of any common solid tumour.
PDAC often remains asymptomatic until the tumor becomes advanced. Common
symptoms include abdominal pain, weight loss, and jaundice. The majority of patients are
diagnosed at late stages when PDAC has already metastasized (Zhang et al., 2019), likely
due to the pancreas being located deep in the abdomen and often lacking early symptoms
until the tumor spreads to other organs. In 60-70% cases, PDAC develops from the head
of the pancreas (Corbo et al., 2012). These cases are often diagnosed earlier because the
head of the pancreas contains the pancreatic duct that joins the lower part of the common
bile duct, which is responsible for carrying bile through the pancreas into the duodenum.
In contrast, PDAC arising from the body and tail of the pancreas usually has a poor
prognosis (Sarantis et al., 2020).
The high mortality rate of PDAC is also due to the resistance these tumours show to most
current cancer treatments. Most traditional cancer therapies, such as chemotherapy,
radiotherapy, and surgery, have limited effects on improving survival. Surgical resection
and chemotherapy with gemcitabine are considered the most effective treatments to
improve the survival rate of early-stage PDAC patients with resectable and locally
advanced tumors, respectively. However, these treatments are not sufficient for late-stage
patients (Sarantis et al., 2020) and have relapse rate up to 80% (Low et al., 2011). For these
reasons, it is essential to elucidate factors that affect the initiation and progression of PDAC
and discover methods of detection and stratification of PDAC. To identify novel targets for
treatment, there is a critical need in identifying and understanding mechanisms that
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underlie the initiation events in PDAC, as well as the potential to increase patient’s survival
rate after diagnosis.

1.1.1

ORIGIN OF PDAC
PDAC originates in the exocrine part of the pancreas. The pancreas is a long-flattened
gland located in the abdomen surrounded by the spleen, liver and small intestine. The
pancreas has two functional components - the exocrine pancreas that produces, stores and
delivers digestive enzymes, and the endocrine islets that regulate blood sugar levels (Zhou
et al., 2018). The exocrine pancreas is composed of acinar cells, which are responsible for
producing and secreting digestive enzymes, and duct cells, which form interposed conduits
that transport enzymes into the small intestine (Backx et al., 2022).
PDAC can originate from acinar cells or duct cells with similar phenotypes but different
modes of tumor progression (Ferreira et al., 2017). Due to the high expression of duct cell
markers and duct morphology, PDAC was originally thought to arise exclusively from duct
cells. However, recent studies show evidence of acinar cells adopting duct cell features,
with acinar cells the most common cell of origin for PDAC (De La et al., 2008; Ferreira et
al., 2017; Xu et al., 2019). Acinar-derived PDAC usually develops via pre-neoplastic
precursors called pancreatic intraepithelial neoplasia (PanINs), which is one of the
precursor lesions in PDAC. Studies also show acinar cells are more sensitive to pancreatic
tumor driver mutations and are more likely to develop into PanIN and PDAC effectively.
Duct cells are more resistant to oncogenic drivers and are less likely to develop to PDAC
(Brembeck et al., 2003; Guerra et al., 2007; Ray et al., 2011), therefore, our models have
focused on expressing oncogenic KRAS within acinar cells.

1.1.2
1.1.2.1

PDAC PROGRESSION AND MORPHOLOGY
ACINAR-TO-DUCT CELL METAPLASIA (ADM)
A key event that can increase the risk of PDAC is a common and reversible process called
acinar-to-duct cell metaplasia (ADM), which can be induced by the pancreatic
inflammation that occurs in pancreatitis (Liu et al., 2016). ADM is a process in which
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pancreatic acinar cells dedifferentiate into progenitor-like cells and then re-differentiate
into duct-like cells with duct cell traits. An ADM lesion is characterized by a lobular
structure consisting of mainly metaplastic duct-like cells, which are proliferative and
replenish the tissue after damage (McDonald, 2022; Fig 1.1). ADM facilitates acinar cell
regeneration and reverses loss of pancreatic tissue due to injury, showing the ability of
acinar cells to adapt to pressures caused by environmental and/or genetic stress (Wang et
al., 2019). However, when oncogenic genetic mutations are acquired and/or environmental
stress is persistent, ADM may become irreversible and lead to low-grade PanINs,
increasing the risk of further progressing to PDAC (Andrew et al., 2020; Storz, 2017).
Multiple genetic and environmental factors have been implicated in regulating the
formation of ADM, including oncogenic KRAS (Hingorani et al., 2003), persistent stress
signalling (Liou et al., 2016), inflammatory cytokines (Liou et al., 2013), loss of cell-cell
and cell-matrix contacts (Greer et al., 2013; Sawey et al., 2007), loss of cell polarity
(Direnzo et al., 2012), and the presence of growth factors that activate epidermal growth
factor receptor (EGFR) (Liou et al., 2016; Storz, 2017). Studies from both human (Liu et
al., 2016; Huang et al., 2021) and mouse models (Collins et al., 2012; Habbe et al., 2008)
identified the essential role of oncogenic KRASG12D in the induction of ADM-like change
in cell culture and in vivo. In mouse acinar cells, oncogenic KRAS changes gene expression
profiles, which results in suppression of acinar-specific genes including carboxypeptidase
A1 (Cpa1) (Livshits et al., 2018) and Amylase (Liou et al., 2013), and activation of ductspecific genes such as cytokeratin 19 (CK19) (Liou et al., 2013), mucin 1 (Muc1) (Zhu et
al., 2007), and Sry-related high-mobility group box 9 (Sox9) (Zhou et al., 2018).
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Figure 1.1 Schematic model of the progression of normal pancreatic acinar cells to
PanIN lesions to PDAC. Oncogenic KRASG12D expression in acinar cells promotes acinar
to duct cell metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN). This
eventually results in PDAC observed in PDAC mice models. PDAC cells release factors
that stimulate surrounding residential fibroblasts into activated myofibroblasts (myCAFs)
and inflammatory fibroblasts (iCAFs). During tumorigenesis, immune cell populations
including T cells, NK cells, and macrophages infiltrate the tumor microenvironment (TME).
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1.1.2.2

PANCREATIC INTRAEPITHELIAL NEOPLASIA (PANIN)
PanINs are the most common type of non-invasive precursor lesion that leads to invasive
PDAC. Generally, PanIN are asymptomatic and microscopic lesions that measure less than
5 mm in diameter (Distler et al., 2014). The progression from PanIN to PDAC is classified
into three different stages according to the level of morphologic dysplasia and
accumulation of genetic alterations: low grade (PanIN-1A and PanIN-1B), intermediate
grade (PanIN-2), and high grade (PanIN-3). Significant genetic and molecular changes take
place in each stage that drive metastasis of PDAC cells, including mutations in KRAS, p53,
and SMAD4 (Guo et al., 2016; Figure 1.1).
Low-grade PanINs arise in metaplastic ductal epithelium and can be observed in healthy
pancreatic tissue (Habbe et al., 2008). PanIN-1A lesions are flat lesions characterized by
simple columnar epithelium with no nuclear dysplasia (Distler et al., 2014). PanIN-1B
lesions are papillary epithelial lesions that are similar to PanIN-1A but show nuclear atypia
and undulating architecture. PanIN-2 are mucinous epithelial lesions that show loss of cell
polarity, with enlarged nuclei that vary in size and shape and have a pseudostratified
appearance. Cytologically, PanIN-2 show moderate architectural atypia, which includes
nuclear crowding, and nuclear hyperchromasia. PanIN-3 exhibit the most severe dysplasia,
which is characterized by extensive loss of nuclear polarity, papillae and cribriform
structure formation, poorly oriented nuclei, and cell clusters bud from the papilla into the
lumen of the duct. PanIN-3 lesions are stratified, predominantly papillary and rarely flat
(Guo et al., 2016; Distler et al., 2014; Hruban et al., 2008; Seeley et al., 2010; Figure 1.1).
The accumulation of genetic alterations is often correlated with the histological progression
of pancreatic carcinogenesis.

1.1.2.3

PDAC
Grossly, PDAC presents as a solid white-yellowish mass with abnormal contours, most
frequently located at the pancreatic head. At diagnosis, PDAC tumors have usually
developed beyond the pancreatic anatomical boundary and infiltrated into neighboring
structures including associated blood vessels, peripancreatic fat tissue, duodenum, or
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stomach (Esposito et al., 2019). PDAC tumors often reach a size between 2-4 cm if
localized in the proximal pancreas, or even larger if localized in the body and tail (Haeberle
and Esposito, 2019). Microscopically, PDAC lesions appear as irregular small pancreatic
ducts consisting of atypical ductal units lined by one or two layers of cuboidal duct cells,
embedding in dense desmoplastic stroma (Korc, 2007). Based on transcriptomic analysis
of PDAC epithelial cells, Moffitt et al. (2015) identified four subtypes of tumors by
separating tumor and stromal gene expression profile. Two tumor-specific subtypes
include classical and basal-like PDAC. Patients with classical PDAC have significantly
higher survival rate and better diagnosis, while basal-like PDAC is associated with poor
diagnosis and clinical outcomes (Moffitt et al., 2015; Shinkawa et al., 2022). The classical
PDAC is characterized by the expression of epithelial markers and higher level of
differentiation, with the presence of fibrosis and inflammation in pancreatic tissues. Basallike PDAC is characterized by the expression of mesenchymal markers and poor
differentiation (Juiz et al., 2020; Shinkawa et al., 2022). Two stromal-specific subtypes are
identified as normal and activated stromal PDAC. Activated stromal PDAC is
characterized by two factors that demonstrated gene expression specifically from the
stromal area. Patients with activated stromal PDAC have worse diagnosis compared to
patients with normal subtype (Moffitt et al., 2015).

1.1.3

GENETIC FACTORS
PDAC tumorigenesis involves progressive accumulation of diverse genetic alterations
including point mutations, insertions, deletions, and amplifications in more than 500 genes
(Lucito et al., 2007). However, genome-wide sequencing studies identified only four
signature genetic mutations for PDAC, including the KRAS oncogene, and tumour
suppressor genes TP53, CDKN2A/p16, and SMAD4 (Waddell et al., 2015). These genetic
alterations are the main cause of the histological changes that occur in different stages of
PDAC progression (Hruban et al., 2008). The majority of PDAC patients carry KRAS and
TP53 mutations. Almost 95% PDAC patients carry at least two out of four mutations, while
KRAS mutations alone was found in 93% patients. It is reported that patients with less
mutations survived significantly longer than patients with more mutations, and that patients
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carrying wild-type KRAS or CDKN2A/p16 also survived significantly longer than those
with oncogenic KRAS (Schlitter et al., 2017).

1.1.3.1

ONCOGENE KRAS
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are the most common
driver genes of PDAC that occur in early preneoplastic lesions (Waddell et al., 2015; Guo
et al., 2016). Approximately 95% of all PDAC patients are found to carry an oncogenic
KRAS mutation (Guo et al., 2016). KRAS is located at chromosome 12p12.1 and encodes
for a small plasma membrane bound GTPase protein called KRAS (21 kDa), which acts as
a molecular switch for multiple downstream signaling pathways. KRAS protein comprises
two functional domains, one of which called the G domain that is responsible for binding
and hydrolysing guanosine triphosphate (GTP). The second domain is the membrane
targeting domain that anchors to the cell membrane and is necessary for the bioactivity of
KRAS. The function of KRAS as a molecular switch is controlled by the intrinsic
guanosine triphosphate (GTP)- guanosine diphosphate (GDP) cycling (Vigil et al., 2010).
In the quiescent state, KRAS is predominantly bound to GDP and is inactive. Extracellular
stimulations such as epidermal growth factor (EGF) bind to the epidermal growth factor
receptor (EGFR) and activate tyrosine kinases (Ardito et al., 2012). This leads to rapid
transition of KRAS from the GDP-bound inactive state to the GTP-bound active state
mediated by guanine nucleotide exchange factors (GEFs) (Vigil et al., 2010). Active KRAS
is capable of recruiting effector proteins and, therefore, regulates more than 80 downstream
intracellular signalling pathways (Buscail et al., 2020). The deactivation of KRAS is
mainly mediated by GTPase-activating proteins (GAPs), which accelerate the hydrolysis
of GTP (Figure 1.2). In general, KRAS couples growth factor receptors on the cell
membrane to intracellular signalling pathways and eventually promotes cell proliferation,
differentiation, migration, and survival by activating various signaling pathways and
transcription factors (Buscail et al., 2020).
Common KRAS variants include G12D, G12V, and G12R, while some less common KRAS
variants include G12C, Q61H, Q61R, representing different types of amino acid changes
due to mutations (Bournet et al., 2016). These are gain-of-function mutations in KRAS that
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cause hyperactivation. Among all the PDAC-associated variants in KRAS, G12D is the
most frequent type of point mutation that accounts for nearly 40% of all KRAS mutations
(Waters and Der, 2018). Two mutational hot spots, G12D and G12V, involve single
nucleotide mutations that induce replacement of the GGT (glycine) sequence by the GAT
(aspartic acid) sequence and by the GGT (valine), respectively (Bournet et al., 2016). These
mutations permanently impair the GTPase activity of KRAS and prevent the conversion of
GTP to GDP, resulting in persistent activation of KRAS independent of extracellular
stimulation (di Magliano and Logsdon, 2013; Jonckheere et al., 2017). The KRAS protein
is therefore capable of constitutively activating various downstream signalling pathways,
leading to cancer cell proliferation, invasion and survival.
Numerous studies revealed that KRAS mutations are the main genetic driver that initiates
the development of PDAC. However, this progression from normal pancreatic tissue to
invasive metastatic PDAC requires additional genetic aberrations and has a long latency
period of 10 to 12 years (Iacobuzio-Donahue et al., 2012; Kanji et al., 2013). Several major
signaling pathways modulated by aberrant KRAS activation include canonical mitogenactivated protein kinase (MAPK), NF-κB, and PI3K-AKT-mTOR signalling pathways
(Figure 1.2; Collisson et al., 2012; Collins, et al., 2014; Jazirehi et al., 2012; Hassan et al.,
2018; Prabhu et al., 2014). The KRAS/MAPK cascade (Figure 1.2) is the best-studied
effector pathway normally activated by EGF, which is the main activating protein for
KRAS signaling. Constitutively active KRAS first binds to and activates the
serine/threonine kinase Raf, which in turn phosphorylates and activates the mitogenactivated protein kinase kinase (MEK1/2).

Subsequently, MEK1/2 phosphorylates

extracellular signal-regulated kinase (ERK1/2), which eventually translocates to the
nucleus where it phosphorylates transcription factors and promotes gene expression
involved in cell-cycle progression, cell proliferation and differentiation (Collison et al.,
2012; Cargnello et al., 2011). Constitutive up-regulation of the MAPK pathway by
KRASG12D promotes acinar cell dedifferentiation and is essential for the maintenance of
PanIN lesions (Collins et al., 2014).
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Figure 1.2 Activation of KRAS protein and downstream intracellular signaling
pathways. Extracellular ligands such as epidermal growth factor (EGF) which are bound
to the epidermal growth factor receptor (EGFR) and leads to interaction with KRAS protein.
The KRAS protein is attached to the cell membrane in order to be activated. KRAS is
activated when bound to GTP and is deactivated when bound to GDP. Intrinsic GTP–GDP
cycling is controlled by guanine nucleotide exchange factors (GEFs) that can convert GDP
to GTP, and by GTPase-activating proteins (GAPs) that can accelerate GTP hydrolysis.
Point mutations (e.g., G12D, G12V) impair the GTPase activity of KRAS and prevents
deactivation. KRAS is therefore constitutively active and is able to upregulate multiple
downstream signaling pathways and nuclear transcription factors, leading to cell
proliferation, differentiation, and survival.
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PI3K-AKT-mTOR is the second major intrinsic intracellular signalling pathway that
contributes to cell cycle regulation (Hassan et al., 2018). KRASG12D constitutively activates
downstream effector Phosphatidyl inositol 3 kinase (PI3K), which in turn phosphorylates
protein kinase B (AKT). AKT can activate multiple downstream transcription factors, one
of which is mammalian target of rapamycin (mTOR), a serine/threonine protein kinase
mainly regulating growth and proliferation of cells. As a master switch of many
downstream effectors, AKT predominantly functions to promote cell survival mediated by
growth factors and to restrict apoptosis (Jazirehi et al., 2012; Hassan et al., 2018).
Overactivation of this pathway in PDAC results in limited cell apoptosis, which therefore
allows cancer cell proliferation and enhanced PDAC aggressiveness (Jazirehi et al., 2012).
The PI3K-AKT-mTOR pathway also plays a role in modulating crosstalk between tumor
cells and the stromal immune cells, which eventually promotes tumor growth and therapy
resistance (Yuan et al., 2008). The third intrinsic signaling pathway is the Nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB). NF-κB is the “matchmaker” of
cancer and cancer-associated inflammation in PDAC (Kabacaoglu et al., 2019). By
activating a transcription factor called activator protein 1 (AP-1), oncogenic KRAS
promotes the production of interleukin-1α (IL-1α), which stimulates constitutive activation
of the NF-κB signaling (Ling et al., 2012). This not only results in the activation of multiple
target genes responsible for proinflammatory and antiapoptotic responses in PDAC, but
also leads to overexpression of sequestosome-1, also known as ubiquitin-binding protein
p62, which positively regulates the feedback loop and further increases NF-κB levels
(Prabhu et al., 2014).
By activating numerous major intrinsic signaling pathways, KRASG12D is able to promote
irreversible ADM and initiate progression to PDAC. However, additional genetic or
environmental factors are required along with KRAS oncogene to promote more
progressive PanIN lesions.
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1.1.3.2

TUMOR SUPPRESSOR GENES
In addition to KRAS, TP53, CDKN2A/p16, and SMAD4 tumor suppressor genes are
mutated in many PDAC cases, with a prevalence of 70%, 21% and 17%, respectively
(Waters and Der, 2018; Maddalena et al., 2021). The presence of additional mutational
burden in tumor suppressor genes can dramatically accelerate the progression of
KRASG12D-mediated PDAC (Hingorani et al., 2005). In contrast to KRAS, TP53,
CDKN2A/p16, and SMAD4 are inactivated in most of PDAC cases, while KRAS is
activated (Hahn & Schmiegel, 1998).
The majority of mutations in tumor protein p53 (TP53) are missense mutations, leading to
excessive production of mutant p53 in tumor cells (Maddalena et al., 2021). Mutations in
TP53 essentially promote metastasis of PDAC by preventing growth arrest or senescence
of cancer cells (Morton et al., 2010). Cyclin dependent kinase inhibitor 2A (CDKN2A)
encodes for the p16 protein, which can negatively regulate the progression of cell cycle
(Zhao et al., 2016). Mutations in CDKN2A result in functional inactivation and
uncontrolled cell growth and differentiation (Zhao et al., 2016). Mothers against
decapentaplegic homolog 4 (SMAD4) mutations are rare in PDAC, but the combination of
SMAD4 mutations with other genetic mutations increase the risk of PDAC. It encodes for
the SMAD4 protein, which acts as an effector protein that activates the transforming
growth factor-β (TGFβ) pathway (Dardare et al., 2020). Given TGFβ primarily plays a role
in cell cycle regulation as a tumor suppressor, alterations in the SMAD4 gene contribute to
promoting the progression of PDAC (Waddell et al., 2015). However, TGFβ can promote
tumour progression at later stages of PDAC, suggesting an opposing role of SMAD4. In
contrast to KRAS, which occur early in the disease, CDKN2A and SMAD4 genes usually
appear in later stages of PDAC such as PanIN-3, when lesions are histologically
recognizable (Kubiczkova et al., 2012; Zhao et al., 2016).

1.1.3.3

GENETIC MODELS OF PDAC
Given the well-known role of oncogenic KRAS in initiating multiple genetic events for
PDAC, studying KRAS mutations has been important in improving our knowledge on the
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transformation process in PDAC and to develop effective treatments. In the past few
decades, transgenic animal models, especially a KRASG12D mouse model, has been widely
used for pathophysiological studies of PDAC (Löhr et al., 2005; Hingorani et al., 2003;
Siveke et al., 2007; Jonckheere et al., 2017). Some commonly used mouse lines were
developed in which KRASG12D was conditionally activated by cre recombinase expressed
from pancreas-specific genes such as pancreatic and duodenal homeobox 1 (Pdx1),
Ptf1a/P48, and Mist1 (Hingorani et al., 2005; Herreros et al., 2012). These models are
named Pdx1cre/+/lox-stop-lox (LSL)-KRASG12D, Ptf1a(P48)cre/+/LSL-KRASG12D, and
Mist1cre/+/LSL-KRASG12D (Herreros et al., 2012). In general, these genetically engineered
mice have cre recombinase targeted to the specific genes to ensure spatially restricted
expression. The cre recombinase then promotes deletion of the LSL region located within
the KRAS gene, but upstream of a mutated, constitutively activate KRASG12D.
Pdx1cre/+/LSL-KRASG12D mice are also known as the KC mouse model. PDX1 is a critical
transcription factor involved in the development of the pancreas. Specifically, PDX1
facilitates growth and lineage specification of pancreatic multipotent progenitor cells
(MPC) during embryogenesis (Kawaguchi et al., 2002; Hingorani et al., 2005). Therefore,
KC mice express pancreas wide oncogenic KRASG12D from early embryonic development
(Guerra et al., 2013). Pancreatic transcription factor 1a (Ptf1a) and MIST1 are two of the
basic helix-loop-helix (bHLH) transcription factors, whose downregulation is often
associated with acinar cell dedifferentiation and loss of acinar cell identity during ADM
(Pin et al., 2001; Johnson et al., 2004; Rodolosse et al., 2004). They coordinate to maintain
the highly differentiated status of acinar cells and prevent the pancreas from undergoing
carcinogenesis (Jakubison et al., 2018). Silencing of Ptf1a and Mist1 genes make acinar
cells more prone to undergo irreversible ADM in the context of KRASG12D hyperactivation
(Adell et al., 2000). Transgenic mouse models using Ptf1a and Mist1 as cre driver genes,
termed Ptf1acre/+KRASG12D (PK model) and Mist1cre/+KRASG12D (MK model), respectively,
induce acinar-specific activation of KRASG12D as they are specifically expressed in acinar
cells to coordinate transcription network. Notably, when PK model is used without an
inducible cre-recombinase, non-specific gene deletion will occur in the pancreas because
Ptf1a is originally express in all pancreatic cells (Jakubison et al., 2018; Azizi et al., 2021).
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Interestingly, many studies reported pancreas-wide hyperactivation of oncogenic KRAS in
adult mice using an inducible Cre/loxP system, resulted in limited spontaneous ADM and
PanIN formation, suggesting KRASG12D alone works inefficiently in driving tumorigenesis
(Guerra et al., 2011). KRAS works more effectively when chronic pancreatitis, a major
risk factor for PDAC, coexists (Carrière et al., 2009; Guerra et al., 2011). KRASG12D
activation, along with an inflammatory environment, can effectively induce formation of
ADM formation and early PanIN lesions (Ferreira et al., 2017).

1.1.4

ENVIRONMENTAL FACTORS
In addition to contributions of genetic and epigenetic alterations, there are many known
modifiable environmental risk factors for pancreatic cancer including tobacco smoking,
alcohol abuse, obesity, diabetes, diet, inactivity, infections, pancreatitis, and certain
abdominal surgeries (Boursi et al., 2017). Many studies have indicated that alcohol
consumption and tobacco smoking are the strongest risk factors at this time, as they are
linked to 60-90% of chronic pancreatitis cases (Pandol & Raraty, 2007; Tsai & Chang,
2019). In addition, international variation and gender differences in the prevalence of
PDAC may be attributed to exposure to environmental risk factors related to different
lifestyles or cultures (Parkin et al., 2010; Bosettin et al., 2012).

1.1.4.1

PANCREATITIS
Pancreatitis is one of most common pathologies in the exocrine pancreas resulting from
inflammation of the pancreas due to premature activity of digestive enzymes inside acinar
cells. In general, enzymes produced by the pancreas are activated after they are transported
into the small intestine to help with digestion and glucose homeostasis in the body. If these
enzymes become activated while still in the pancreas, they cause irritation of pancreatic
cells and result in pancreatitis. The pathophysiology of pancreatitis is characterized by
extracellular fluid that causes swelling of tissues, separation of lobule and acini, loss of
acinar cell zymogen granules, and enlarged acinar lumen (Magana-Gomez et al., 2006).
The most common causes of pancreatitis are alcohol abuse and gall stones. Ethanol mainly
induces the initiation of pancreatitis by improper activation of digestive zymogens within
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acinar cells and soluble N-ethylmaleimide sensitive fusion protein (NSF) attachment
receptor (SNARE) proteins that are required for the fusion of zymogen granules (Clemens
et al., 2014). During pancreatitis, the tissue usually displays histological features such as
immune cell infiltration and fibrosis (Yadav and Lowenfels, 2013). Pancreatitis can be
acute, which happens suddenly and lasts for a few days, or chronic, which occurs over
years. Chronic pancreatitis (CP) are the major risk factors for human PDAC (Guerra et al.,
2007; Vujasinovic et al., 2020). A large nationwide study conducted by Kirkegard et al.
revealed that AP can also promote PanIN formation, while the relationship between AP
and PDAC is still debatable. However, CP is proposed to be the most common cause of
PDAC initiation as nearly 60% patients with CP appear to develop PanINs to different
extents, with 4% of which had high-grade PanIN (Hruban et al., 2008). People with
hereditary pancreatitis have a 40-55% possibility of developing PDAC in their lifespan
(Yadav and Lowenfels, 2013). For these reasons, pancreatitis models using the
cholecystokinin agonist cerulein are widely used in research involving PanINs and PDAC.

1.1.4.2

EXPERIMENTAL MODEL OF PANCREATITIS
Pancreatitis induced in the mouse model by cerulein is currently the most widely used
experimental model to study PDAC (Hyun and Lee, 2014). This method is based on the
mechanism that cerulein activates high levels of nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase, the most abundant reactive oxygen species in acinar cells
during inflammation and apoptosis, and causes oxidative stress in cells (Kim, 2008).
Oxidative stress is linked to pancreatic inflammation and is the major pathogenic factor
contributing to pancreatitis (Vaziri, 2004). In brief, cerulein causes pancreatic tissue
damage by inducing necrosis, inflammation, and ADM transition. Cerulein-induced
pancreatic injury usually allows full recovery within 7 days (Mallen St. Clair et al., 2012).
However, in the presence of oncogenic KRAS, pancreatitis-induced ADM rapidly
progresses to PanIN and PDAC instead of re-differentiating back into acinar cells for tissue
recovery (Ferreira et al., 2017). Cerulein-induced pancreatitis can be either chronic (with
repeated dosing over up to 5 weeks) or acute (Huang et al., 2013). Alternative methods to
induce chronic or acute pancreatitis (AP) in mouse models include continued alcohol
consumption that causes lipopolysaccharides (LPS)-induced pancreatic injury (Vonlaufen
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et al., 2011), group B coxsackieviruses (CVB)-induced pancreatitis (Tracy et al., 2000),
and intake of choline deficient ethionine-supplemented (CDE) diet (Ida et al., 2010).

1.2

TUMOR MICROENVIRONMENT (TME)

As PDAC develops, tumor cells accumulate genetic and epigenetic alterations and result
in significant dysregulation of signaling pathways that cause histological changes in the
progression of PDAC, but also reprogram the surrounding microenvironment (Sousa, 2014;
Tiomsland et al., 2011; Whatcott et al., 2015). These alterations eventually alter normal
physiological function of the stroma, which normally supports tissue regeneration and
restrains tumor growth with its component of connective tissues, immune cells, fibroblasts,
and vasculature, and generate a favorable tumor microenvironment (TME) (Dunne &
Hezel, 2015; Foster et al., 2018). Unlike most other tumors, the PDAC TME can make up
the ~90% of the tumor volume, while it could also be as low as 20% depending on high
and low cellularity (Karagiannis et al., 2012). Generally, the TME provide cancer cells
with innate chemoresistance through the dense stromal compartment, which acts like a
physical barrier that prevents successful drug delivery and immune cell infiltration
(Provenzano et al., 2012). As an important feature of PDAC, the heterogenous TME is an
ecosystem mainly characterized by infiltration of immune cells, dense stroma, and
proliferating cancer-associated fibroblasts (CAFs) (Öhlund et al., 2017). It also contains
extracellular matrix (ECM) proteins and soluble proteins (cytokines, growth factors) that
are believed to contribute to the aggressiveness and drug resistance of PDAC tumor
(Figure 1.3). The interactions between TME components and cancer cells are essential for
tumor cell survival, proliferation, and development.

1.2.1

CANCER-ASSOCIATED FIBROBLAST (CAF)
Fibroblasts are spindle-shaped cells responsible for secreting extracellular matrix proteins
and collagen and build the structural framework in tissues. Fibroblasts play an important
role in inflammation and cancer formation by modifying the microenvironment. Cancer
cells can stimulate surrounding fibroblasts by releasing stimulating factors, such as TGFβ,
that give rise to CAFs (Dvorak, 1986; Yu et al., 2014). A major source of CAFs is activated
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pancreatic stellate cells (PSCs), which primarily derive from bone marrow mesenchymal
stem cell (Öhlund et al., 2017; Haber et al., 1999). PSCs are the predominant type of
fibroblast cell located in exocrine pancreas. In healthy pancreas, PSCs are quiescent starshaped cells and control the production of ECM proteins during the wound healing process
(Tomasek et al., 2002). However, in PDAC, PSCs are activated by stimulating factors
released by cancer cells and become high in abundance with myofibroblast-like phenotypes
(Murray et al., 2022). Activated PSCs constitute almost half of the stromal area and can
produce a large amount of the ECM components, including fibronectin, hyaluronic acid
(HA), and collagen I and III, which significantly promote desmoplasia (Binkley et al.,
2004). The dense ECM is the main cause of high interstitial fluid pressure (IFP) within the
stroma, which limits drug infusion and promotes chemotherapy and radiotherapy resistance
(Provenzano et al., 2012). Excessive deposits of ECM and collagen fibers also contribute
to the development of pancreatic fibrosis, resulting in stiffness of pancreatic tissue (Ferdek
& Jakubowska, 2017). The abilities of PSCs to interact with PDAC cells and form a dense
fibrotic stroma facilitate are usually related to the aggressiveness of PDAC and therapy
resistance.
PSCs can differentiate into at least two CAF subpopulations with diverse phenotypes and
functions. Myofibroblastic CAFs (myCAFs) are located in close proximity to tumor cells,
while inflammatory CAFs (iCAFs) are located more distantly from tumor cells (Öhlund et
al., 2017) (Figure 1.3). myCAFs are characterized by high expression level of α-smooth
muscle actin (α-SMA), an activated fibroblast marker, and are responsible for remodelling
of ECM. myCAFs can be both anti-tumor and pro-tumor (Ozdemir et al., 2014). Previous
studies revealed that specific deletion of myCAFs in the stroma restricted the development
of desmoplasia and tumor aggressiveness (Ozdemir et al., 2014) and high myCAF levels
are often associated with poor PDAC diagnosis (Hu et al., 2022). In contrast to myCAFs,
iCAFs lack α-SMA expression and are characterized by high expression of interleukin 6
(IL-6). iCAFs play a significant role in the immune regulation by interacting with immune
cells, which contribute to immunotherapy resistance of cancer cells. Cancer cells release
interleukin 1 (IL-1) that can reprogram iCAFs to produce cytokines and chemokines, such
as IL-6, chemokine (C-X-C motif) ligand 1 (CXCL1), chemokine (C-X-C motif) ligand 12
(CXCL12), and chemokine (C-C motif) ligand 2 (CCL2), which enhance immune cell
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Figure 1.3 The tumor microenvironment in PDAC is composed of several different
cell types. The TME is composed of PDAC tumor cells, inflammatory, myofibroblastic
and antigen-presenting CAFs, T lymphocytes, macrophages, vasculature, and desmoplastic
stroma. Cancer cells release cytokines and chemokines and interact with surrounding
stromal cells through paracrine interaction to promote a microenvironment that favors the
growth of tumor cells. ECM, extracellular matrix.
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activation through paracrine interactions (Ohlund et al., 2014). PDAC with a higher iCAF
abundance is often linked to more reprogrammed metabolism and a higher inflammatory
state, suggesting a better response to immunotherapy (Hu et al., 2022). Most studies
consider iCAFs as a protective factor against PDAC growth because high iCAF numbers
are associated with better diagnosis. However, other studies suggest iCAFs favor cancer
progression by synthesizing enzymes responsible for the production of hyaluronan (HA),
a major component of the ECM that produces solid stress in PDAC tumor (Elyada et al.,
2019).
Recently, genome-wide studies have identified a third CAF subtype termed antigenpresenting CAFs (apCAFs) based on single-cell RNA-seq (scRNA-seq) analysis. apCAFs
are capable of expressing high level of major histocompatibility complex class II molecules
(MHC II complex), which is able to present antigens to specific T cells (Huang et al., 2022).
Therefore, apCAFs are hypothesized to induce immune suppression by inducing specific
T cells into regulatory cells (Treg), which can inhibit the immune response in PDAC and
contribute to tumorigenesis (Elyada et al., 2019; Huang et al., 2022).
CAFs are also responsible for promoting angiogenesis in PDAC. PDAC is a solid tumor
with high interstitial fluid pressure and low microvascular density (MVD), resulting in
hypoxic microenvironment. For aggressive tumorigenesis to occur, CAFs secrete
angiogenic factors, including vascular endothelial growth factor (VEGF) and fibroblast
growth factor (FGF), to induce formation of new blood vessels that provide more oxygen
and nutrients and remove metabolic waste for better growth of cancer cells (Longo et al.,
2016). In summary, CAFs play a role in tumorigenesis, metastasis, drug resistance,
angiogenesis, and immunosuppressive phenotypes of PDAC, which can either be protumorigenic or anti-tumor.

1.2.2

IMMUNE CELLS
Immune cells are essential components of the TME and affect the progression of PDAC
(Mahajan et al., 2018). While PDAC develops, cancer cells are recognized as foreign by
the immune system, resulting in immune cells infiltration and accumulation within the
stroma. The crosstalk between immune cells and the TME is complicated, as immune cells
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can supress or promote tumor growth depending on the context. The immune system
generally has two types of cells: innate immune cells and adaptive immune cells. The innate
immune response is a non-specific defence mechanism that detects and destroys tumor
cells. Innate immune cells include macrophages, neutrophils, dendritic cells. The adaptive
immune response involves cancer cell detection and destruction with specialized immune
cells and antibodies. Adaptive immune cells include predominantly T cells, B cells, and
natural killer (NK) cells.
The infiltration of tumor-associated macrophages (TAMs) is observed very early in the
PDAC development (Feig et al., 2012). Cancer cells can reprogram macrophages by
releasing cytokines, such as interleukin 4 (IL-4), and switch them from inflammatory M1
subtype to immune-suppressive M2 subtype, which has tumorigenic functions. TAMs
support PDAC cell invasion and aggressiveness mainly by stimulating angiogenesis and
inhibiting activation of anti-tumor T effector cells and NK cells (Borrego et al., 1998).
Tumor-associated antigens (TAAs) activate T cells via MHC complex and, therefore,
trigger enhanced anti-tumor immune responses. In the initial stages of PDAC, T
lymphocytes are carried through blood vessels and migrate to small ducts to eliminate the
abnormal PanIN cells. When the amount of activated T cells reaches a threshold, the
regulatory T cells, or Tregs, become activated to negatively regulate the action of T cells
(Tanaka, 2017). CD8+ cytotoxic T cells are one of the subpopulations of T cells responsible
for detecting abnormal TAAs and target cancer cells for destruction (Zamora et al., 2018).
Cytotoxic T cells also contribute to tumor suppression by inhibiting angiogenic process.
Therefore, the presence of cytotoxic T cells in the TME usually represent positive
prognosis in PDAC patients (Tanaka, 2017). However, it is reported that CD8+ tumor‐
infiltrating lymphocytes (TIL) can be inhibited by TAMs (Etzerodt et al., 2019). Cancer
cells release TGF-β that promotes the proliferation of Tregs, which secrete immunesuppressive cytokines and result in fewer T effector cells infiltration in the TME. In this
manner, Tregs restrict the immune response and is often associated with adverse prognosis
(Tanaka, 2017).

22

1.3

EPIGENETICS

Research into the epigenomics of PDAC has revealed that PDAC initiation and progression
is associated not only with genetic alterations, but also epigenetic changes that may play a
critical role in cancer metastasis by regulating the expression of genes associated with
tumor progression and survival (Thompson et al., 2015; Abukiwan et al., 2018). Three
identified types of epigenetic regulations include DNA methylation, histone modifications,
and noncoding RNAs (Ennis, 2014). These epigenetic processes result in reversible and
heritable modifications to the chromatin, or within the DNA itself, which affects the
expression of genes without changing the DNA sequence.
This is achieved by changing the chromatin structure surrounding genes and regulating
accessibility to the promoter region (Shen & Laird, 2013). The crosstalk between
epigenetic factors and major signaling pathways associated with cell proliferation and
apoptotic control may have implications in the development of PDAC (Lomberk et al.,
2015). There is evidence suggesting dysregulation of epigenetic pathways normally
contributes to the tumorigenesis of cancer (Paradise et al., 2018). PDAC usually involves
deregulation of several epigenetic regulators, including methyltransferases, Enhancer of
Zeste Homolog 2 (EZH2), and histone deacetylases (HDACs) (Chan-Seng-Yue et al.,
2020). Understanding the epigenomics of PDAC and its extensive control over cancerrelated genes may help broaden anti-cancer therapeutic options in PDAC.

1.3.1

DNA METHYLATION
DNA methylation is the addition of a methyl group to the 5' carbon of cytosines mediated
by DNA methyltransferases (DNMTs), forming 5-methylcytosine (5mC) (Abukiwan &
Berger, 2018). This epigenetic reaction occurs mainly at CpG islands, which are genomic
regions where C and G bases appear at a higher frequency than predicted and are usually
located in the gene promoter regions. Methylation of CpG islands at promoter region
interferes with the transcription of the gene, reducing access and, therefore, suppressing
gene expression (Antequera & Bird, 1999). DNA methyltransferase 1 (DNMT1),
DNMT3A and DNMT3B are major enzymes catalyzing methylation of DNA. DNMT3A
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and DNMT3B facilitate de novo DNA methylation, while DNMT1 is responsible for the
maintenance of parental methylation patterns (Cheng et al., 2008; Abukiwan & Berger,
2018). Excessive DNA methylation of several genes due to DNMT1 overexpression was
detected in 81% of PDAC patients, while less than 4% of healthy individuals presented
DNA methylation on these genes in the pancreas (Brancaccio et al., 2019). Silencing of
key tumor suppressor genes as a result of DNA methylation is believed to contribute to
tumorigenesis of PDAC (Tan et al., 2009). Interestingly, a recent study revealed that not
only cancer-associated genes, but also DNMTs themselves are differentially methylated in
PDAC (Vincent et al., 2011).

1.3.2

MICRORNA
MicroRNAs (miRNA) are small noncoding, single strand-RNA molecules consisting of
20-23 nucleotides. One of the major mechanisms by which miRNAs regulate gene
expression is by binding to the untranslated region of mRNAs and lead to its degradation
of reduced translation (Ambro, 2004). In healthy cells, miRNAs are responsible for
regulating the expression of about 60% protein coding genes involved in cell differentiation,
proliferation, and apoptosis (Winter et al., 2009). The machinery of miRNA has been
implicated in physiological and pathological development of various cancers (Abukiwan
& Berger, 2018). Many PDAC studies have revealed that miRNAs are dysregulated in the
presence of oncogenic KRAS, resulting in increased expression of pro-oncogenes or
prohibited expression of tumor suppressor genes (Yonemori et al., 2017). In general,
miRNAs mainly have two distinct roles in PDAC, one as tumor suppressors (TSmiRs), and
the other as oncogenes (OncomiRs) (Kunej et al., 2012; Abukiwan & Berger, 2018). On
the other hand, mutant tumor suppressor genes such as p53 can also downregulate miRNA
transcription, resulting in increased cancer cell proliferation and survival (Sohn et al., 1997;
Zhang et al., 2010).

1.3.3

HISTONE MODIFICATIONS
Histone modifications regulate gene transcription by affecting the structure of chromatin,
whose basic unit is the nucleosomes (Abukiwan & Berger, 2018). Each nucleosome
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consists of a small region of DNA (147 base pairs) wrapped around an octamer of eight
histone proteins – two each of H2A, H2B, H3, and H4 (Audia & Campbell, 2016). There
are many histone modifications including methylation, acetylation, phosphorylation, and
ubiquitination, all of which correlate to specific outcomes on gene expression.
Histone methylation is a reversible modification of chromatin where methyl groups are
added to the histone tail by histone methyltransferases (HMTs) or removed by histone
demethylase (HDMs) (Hyun et al., 2017). Histone methylation usually occurs on the
residues of arginine, lysine, and histidine, while lysine alterations are the most common
modification in PDAC (Abukiwan & Berger, 2018). Methylation of lysine residue is
coordinated by histone lysine methyltransferases (KMTs), which can either be associated
with transcriptional repression (H3K9, H3K27, and H3K20 trimethylation) or activation
(H3K4, H3K36, and H3K79 trimethylation) of genes (Abukiwan & Berger, 2018). Among
KMTs, one of the subfamilies termed EZH2 is a H3K27me3-specific histone lysine
methyltransferase (HKMT), able to transfer up to three methyl groups to this residue (Black
et al., 2012). Increased expression of EZH2 occurs in many solid cancers, including PDAC,
and is believed to have effects on the malignancy of PDAC (Wang et al., 2015; Abukiwan
& Berger, 2018).
Histone acetylation is a process by which the lysine residues from the histone are acetylated
with an acetyl group by histone acetylases (HATs) or deacetylated by histone deacetylases
(HDAC) (Abukiwan & Berger, 2018). Lysine acetylation results in relaxation of chromatin
structure and make the DNA accessible to transcription factors (Grunstein, 1997). The
balance between histone acetylation and deacetylation is a key in regulating critical gene
expression in cells, and unbalanced activity of these enzymes may result in malignant
transformation and tumorigenesis in PDAC (Schneider et al., 2011). Recent studies showed
a role of HDACs/HATs in the activation of expression of many tumor suppression genes,
and the hyperactivation of HDACs is associated with cancer cell proliferation and impaired
cell apoptosis regulation (Sato et al., 2004; Haefner et al., 2008).
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1.4

ENHANCER OF ZESTE HOMOLOGUE 2 (EZH2)

Numerous studies have revealed that in addition to genetic alterations, abnormal epigenetic
regulation is also a determinant of tumorigenesis of various cancers (Thompson et al., 2015;
Abukiwan et al., 2018). The aberrant expression of a widely known epigenetic regulator,
enhancer of zeste homologue 2 (EZH2), has been implicated in the tumorigenesis of PDAC
using transgenic mouse model and human PDAC samples (Patil et al., 2020).
EZH2 is a histone methyltransferase encoded by the EZH2 gene, located at chromosome
7q35 in human genome, and contains 20 exons with 746 amino acid residues (Cardoso et
al., 2000). EZH2 is a key member of the polycomb group (PcG) protein family. PcG is a
group of proteins that determine cell fate mainly by epigenetically repressing transcription
of genes involved in differentiation and proliferation. PcG proteins form two core
complexes, polycomb repressive complexes 1 and 2 (PRC1 and PRC2) (Sauvageau &
Sauvageau, 2010). They both play a crucial role in transcriptional suppression of genes
through histone tail modification and subsequent chromatin compaction (Duan et al., 2020).
Specifically, PRC2 is responsible for mono-, di- and tri-methylation of histone 3 at lysine
27 (H3K27me2/3), while PRC1 monoubiquitylates lysine 119 of histone H2A
(H2AK119ub) (Cao et al., 2002; Pengelly et al., 2013). PRC2 is highly conserved in
various animals and plants in terms of its function (Chica et al., 2017). PRC2 composed of
four main subunits including EZH2, embryonic ectoderm development (EED), suppressor
of zeste 12 homolog (SUZ12), and retinoblastoma-binding protein 4/7 (RBBP4/7)
(O’Meara, 2012; Figure 1.4). PRC2 performs its function mainly through the core
enzymatic subunit EZH2, which catalyzes trimethylation of H3K27 in the cell nucleus and
leads to transcriptional silencing of target genes (Völkel et al., 2015). The EZH2 protein
has five domains, EED-interaction domain (EID), homologous domain I, homologous
domain II, cysteine-rich domain (CXC domain), and SET domain (Laible et al., 1997). The
evolutionally conserved SET domain consists of 130-140 amino acids and was initially
recognized in and derived from three Drosophila proteins: the suppressor of variegation 39 (Su(var)3-9), the Enhancer of zeste (E(z)), and the trithorax-group chromatin regulator
trithorax (Trx) (Yao et al. 2016; Nutt et al., 2020). The SET domain maintains histone
methyltransferase activity of EZH2, and this enzymatic process is facilitated by the CXC
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Figure 1.4 Model of the PRC2 complex. Enhancer of Zeste Homologue 2 (EZH2)
interacts with Suppressor of Zeste 12 (SUZ12) and embryonic ectoderm development
(EED) to form the Polycomb repressive complex 2 (PRC2). EZH2 has a SET domain which
serves as the methyltransferase for PRC.
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domain N-terminal that helps assemble all subunits for proper PRC2 function (Simon et
al., 2008). EZH2 has a close homolog, EZH1, which also acts as a methyltransferase of
H3K27 and forms an alternative PRC2 with EED and SUZ12. Despite the similarities
between EZH1 and EZH2, they function independently of each other and have distinct
activities and expression patterns. EZH1 expression is detected in both normal cells and
cancer cell lines, while EZH2 is primarily highly expressed in proliferating cells. The PRC2
complex with EZH2 shows considerably higher methyltransferase activity compared to the
EZH1-containing PRC2 complex (Margueron et al., 2008).

1.4.1

MECHANISMS OF EZH2
EZH2 has both canonical and non-canonical roles in supressing transcription of target
genes. PRC2-dependent H3K27me3 is the major canonical pathway of gene silencing
mediated by EZH2 (Patil et al., 2020). In normal condition, the methyltransferase function
of EZH2 is facilitated by EED and SUZ12, the other two core subunits of PRC2. When the
PRC2 complex is assembled, EED can recruit PRC2 to H3K27 sites at promoter regions
of target genes and stimulate the methyltransferase activity of EZH2. SUZ12 helps
maintain the integrity of the PRC2 complex and stabilizes EZH2 activity (Cao & Zhang.,
2004). Once PRC2 is recruited to the chromatin, the SET domain catalyzes successive
methyl transfers that yield mono-, di- or trimethylated lysine, each has distinct functions
(Zee et al., 2010).
Most H3K27 residues are dimethylated in cells, while only 15% regions are trimethylated.
Although H3K27me2 mainly serves as a substrate for further EZH2-mediated
trimethylation, it also prevents histone tails from being acetylated, which normally
antagonizes the silencing effect of EZH2 (Tie et al., 2009). H3K27me3 is a stable
chromatin mark associated with repression of gene expression, normally associated with
cell fate determination and development (Yin et al., 2019). H3K27me3 acts as a docking
site for recruiting chromosomal regulators that results in changes in chromatin structure,
which facilitate chromatin compaction and eventually promote transcriptional silencing of
downstream genes (Wang et al., 2016). Recent studies revealed that polymerase (Pol) II is
found in H2K27me enriched promoters with a low transcription level detected, suggesting
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RNA Pol II-mediated transcription elongation could be paused due to chromatin structure
changes (Stock et al., 2007; Zhao et al., 20017). In general, the major role of EZH2 in cells
is to repress tumor suppressor genes through H3K27me3 and regulate cell proliferation,
apoptosis, and cell cycle (Huang et al., 2021).
Numerous studies have also revealed non-canonical roles of EZH2 (He et al., 2012; Lee et
al., 2012). This includes non-histone protein methylation, which can either be performed
in a PRC-dependent or -independent fashion (He et al., 2012). Increasing evidence suggests
EZH2 can induce methylation on multiple non-histone substrates, including transcription
factors and chromatin-associated proteins. Specifically, proteins with a similar sequence to
the methylated domain of H3K27, which is termed the amino acid sequence R-K-S, can be
directly methylated on the lysine residue by EZH2 (Lee et al., 2012). However, the
biological consequences of non-histone methylation by EZH2 are context dependent.
EZH2 can also mediate PRC2-independent gene transactivation. Protein kinase B
phosphorylates EZH2 in serine 21 (Ser21). Phosphorylated EZH2 directly methylates
multiple transcriptional factors independently of the PRC2 complex. For instance, EZH2
activates the signal transducer and activator of transcription 3 (STAT3) signaling pathway
by methylating STAT3 (Kim et al., 2013). In castration-resistant prostate cancer (CRPC),
EZH2 is capable of methylating androgen receptor (AR) and promoting downstream gene
transcription and tumor growth (Xu et al., 2012). EZH2 can directly bind to the promoter
region of target genes as a transcription factor. For example, EZH2 can bind to the promoter
of transcription factor RelB and activate expression, which helps maintain the self‐renewal
of breast cancer tumor‐initiating cells (Laurence et al., 2016). However, evidence suggest
noncanonical EZH2 activities are more evident in cancers, especially when EZH2 is
overexpressed (Xu et al., 2015)
Through the three distinct mechanisms mentioned above, EZH2 is capable of regulating
various signaling pathways involved in cell cycle, apoptosis, DNA damage repair, and cell
fate determination (Nutt et al., 2020; He, 2016). Due to the dramatic functions of EZH2 in
various biological processes within the cell, alterations in EZH2 activity can be related to
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many cancers, including PDAC. Hence, elucidating the role of EZH2 in the initiation and
development of PDAC becomes important for potential therapy development.

1.4.2

IMMUNE MODULATORY FUNCTION OF EZH2
In vitro studies revealed that EZH2 enhances PDAC cancer cell proliferation in cell culture.
However, EZH2 plays an opposing role as a suppressor of pancreatic carcinogenesis in
mouse models in vivo, indicating that tumor microenvironment may affect the role of
EZH2 (Ougolkov et al. 2008; Mallen-St Clair et al., 2012). Oncogenic activation of EZH2
mediates aberrant epigenetic changes not only in pancreatic tumor cells but also immune
cell populations, leading to alterations in expression of critical genes involved in cell fate
determination and immune dysfunction in the PDAC TME (Chiappinelli et al., 2016).
Increasing evidence suggest that, in addition to regulating pancreatic cell plasticity, EZH2
plays an important role in mediating cellular pathways involved in immune invasion and
resistance of PDAC cells (Chiappinelli et al., 2016; Jones et al., 2019). Dysregulation of
EZH2 function has been observed in many tumor-infiltrating immune cells in the TME
including T cells, Tregs, and TAMs and chronic changes in the epigenetic landscape due
to EZH2 were widely demonstrated in CD8+ and CD4+ T cells (He et al., 2017). EZH2
promotes the survival and proliferation of effector T cells, while low EZH2 levels in T cells
normally leads to poor prognosis (Karantanos et al., 2016). In the PDAC TME, however,
the percentage of T cells expressing EZH2 is much lower than in normal tissues, suggesting
cancer cells may block the expression of EZH2 in T cells to restrict T cell-mediated
immunity (He et al., 2017). Inhibition of EZH2 activity caused repressed function of tumorspecific effector T cells and therefore favors immune suppression and tumor metastasis
(Zhao et al., 2016). Tregs are known to negatively affect anti-tumor immunity in PDAC by
controlling effector T cell activity (Adeegbe & Nishikawa, 2013). Tumor cells can release
factors that convert CD4+ T cells into Tregs. EZH2 is upregulated in activated Tregs (Wang
et al., 2018). Epigenetic changes mediated by EZH2 is found essential for the recruitment
of tumor-infiltrating Tregs and the repression of immune-mediated tumor control (Wang
et al., 2018; Curiel et al., 2004). Taken together, these results demonstrate that EZH2 may
have various effects on immune cell populations and associated tumor progression and the
consequences are context dependent.
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1.4.3

ALTERATIONS OF EZH2 IN PDAC
EZH2 plays a critical role in mediating H3K27me3 through the canonical pathway,
inducing transcriptional silencing of regulatory genes involved in cell differentiation,
lineage specification, and tissue renewal (Mallen-St Clair et al., 2012). Therefore,
alterations of EZH2 activity and function have been implicated in various cancer
pathologies, including PDAC (Völkel et al., 2015). In particular, overexpression of EZH2
is frequently correlated with advanced human PDAC progression and poor prognosis,
making EZH2 a potential target for anti-cancer therapy (Kim et al., 2015). In PDAC, EZH2
is important in regulating acinar cell reprogramming and tumorigenesis. EZH2 is regularly
overexpressed in about 68% of human PDAC cases, while almost 90% progressive PDAC
cells accumulate EZH2 in the nucleus (Ougolkov et al., 2008).
Although pancreatic regeneration from injury is largely dependent on acinar cell redifferentiation promoted by EZH2-mediated transcriptional silencing of various genes,
overexpression of EZH2 can switch tumor suppressor genes off, thus promoting oncogenic
factors for cell proliferation and metastasis. Therefore, excessive EZH2 expression and
activity in the pancreas is often linked to advanced stages of pancreatic tumorigenesis and
progression toward invasive PDAC (Versemann et al., 2022). In the initial stages of the
carcinogenesis, however, EZH2 is transiently upregulated to facilitate pancreatic tissue
regeneration. Loss of EZH2 at early stage leads to uncontrolled expansion of proliferative
acinar cells and acceleration of KRAS-driven PDAC progression (Mallen-St Clair et al.,
2012). In addition to acinar cells, human embryonic stem cells with EZH2 deficiency
showed compromised self-regeneration and lack of cell differentiation (Collinson et al.,
2016). Chen et al (2017) demonstrated EZH2 can transcriptionally repress the
calcium/calcineurin-responsive nuclear factor of activated T cell (NFATc1) gene, which
encodes for a key transcription factor responsible for malignant transformation of cells and
enable redifferentiation and regeneration of acinar cells. However, constitutive activation
of KRAS oncogene can invert EZH2-mediated effects on many intracellular signaling
pathways, which serves to transcriptionally activate instead of repressing genes associated
with cell differentiation and proliferation (Chen et al., 2017).
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KRAS-signaling has been shown to have profound effects on EZH2 function and activity
(Mallen-St Clair et al., 2012; Chen et al., 2017). KRAS-mediated PDAC is often accelerated
by deletion of EZH2. In previous studies, Chen et al. (2017) suggested the presence of
EZH2 resulted in a slight decrease in the level of pancreatic lesions in pancreas of 2-3
months old mice in the context of KRASG12D hyperactivation. In 6-month-old mice,
however, the loss of EZH2 results in decreased level of pancreatic carcinogenesis and
PanIN lesions (Chem et al., 2017). Conversely, Mallen St Clair et al. (2012) showed EZH2
is required for tissue repair by promoting gene expression involved in cell regeneration and
proliferation, impaired acinar cell regeneration and enhanced KRASG12D-driven neoplasia
(Mallen-St Clair et al., 2012). These contradictory findings may suggest flaws in the mouse
models used or distinct, temporal roles for EZH2 in KRAS-mediated PDAC progression.

1.5

RATIONALE, HYPOTHESIS AND OBJECTIVES

Rationale: Although progress has been made to understand the role of EZH2 in PDAC
progression, the exact molecular mechanisms underlying the effects of EZH2 on KRASdriven PDAC are largely unknown. Therefore, further investigation is required to identify
specific roles of EZH2 in the context of KRAS-mediated PDAC. In previous studies, EZH2
deletion occurred at early stages of pancreatic development, which may affect the
differentiation status of the cells. In addition, the Cre driver used was targeted to the Ptf1a
locus, which makes these mice haplo-insufficient for PTF1A, which may also affect acinar
cell gene expression. In this study, EZH2 will be deleted in adult pancreatic tissues after
acinar cells are fully mature.
Hypothesis: I hypothesize that EZH2 restricts KRAS-driven initiation of PDAC in acinar
cells in response to injury.
Objectives:
1. Determine if loss of EZH2 after acinar cell differentiation enhances Kras-driven PanIN
formation following pancreatic injury in vivo
2. Determine whether the acinar-specific loss of EZH2 increases KRAS-mediated ADM in
an ex vivo culture.
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CHAPTER 2: MATERIALS AND METHODS
2.1

MOUSE STRAINS AND HANDLING

All procedures and methods of mouse colony maintenance and mouse handling were
approved by the University of Western Ontario Animal Care Committee (Protocols 2020157 and 2020-158). Mice were housed in a pathogen-free facility with abundant food and
water supply and exposed to a 12-hour light/dark cycle under guidelines approved by the
Canadian Council for Animal Care. Mice carrying creERT targeted to the Mist1 allele
(Mist1+/creERT) were generated to allow for inducible acinar cell-specific gene deletion
through the cre-LoxP system. CreERT is activated by tamoxifen and allows cre
recombinase to translocate to the nucleus, where it recognizes specific DNA sequences
called loxp sites and deletes the DNA sequence between loxp sites (Johnson et al., 2004).
Mist1+/creERT mice were bred with mice containing an EZH2 allele with the SET domain
(exons 16-19) flanked by loxP sites (Ezh2SET) and/or mice containing a constitutively
active KRASG12D allele downstream of loxp sites flanking a stop codon within the
endogenous KRAS allele (lox-stop-lox; LSL, KRASLSL-G12D/+ mouse). The resulting lines
include Mist1creERT/+KRASLSL-G12D/+Ezh2SET/SET (referred to as KRASLSL-G12D/+Ezh2SET or
KE), Mist1creERT/+KRASG12D/+, and Mist1creERT/+Ezh2SET/SET (Figure 2.1). Genotypes of
mice were determined at time of weaning and confirmed after experiments through PCR
(polymerase chain reaction) of DNA obtained from ear punches using gene-specific
primers shown in Table 2.1. All experiments were carried out with adult mice (2-4 months)
from Mist1+/creERTKRASG12D/+Ezh2SET mouse strain on a C57Bl6 background.
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Figure 2.1 Generation of triple-transgenic mice and the experimental timeline. (A)
Schematic experimental timeline of cerulein-induced acute pancreatic injury model and
time points at which tamoxifen and cerulein were administered. Tamoxifen was given in
three doses as indicated in 2 mg per mouse each time. Cerulein was administered through
eight hourly intraperitoneal (IP) injections of 50 mg/kg of body weight (B) Schematic
representation of the transgenic lines and how KRASG12D and EZH2DSET were generated
by expressing an inducible cre recombinase from the Mist1 gene in acinar cells following
tamoxifen exposure. The SET domain is encompassed by exons 16-19 on the EZH2 allele.
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Table 2.1 DNA primers used for genotyping

Gene

WT/Mutation

Forward

Reverse

Amplicon
Length

Mcre

WT

Cre-ERT

KRASG12D

WT

G12D

Ezh2

WT/SET

5'-

5'-

GGTTTAAGCAAATT

GAAGCATTTTCCAGGT

GTCAAGTACGG 3'

ATGCTCAG 3'

5'-

5'-

ATAGTAAGTATGGT

GAAGCATTTTCCAGGT

GGCGGTCAGCG 3'

ATGCTCAG 3'

5'-

5'-

GTCTTTCCCCAGCAC

AGCTAGCCACCATGGC

AGTGC 3'

TTGAGTAAGTCTGCA 3'

5'-

5'-

CTCTTGCCTACGCCA

AGCTAGCCACCATGGC

CCAGCTC 3'

TTGAGTAAGTCTGCA 3'

5'-

5'-

AGACCCCTGGGGCT

CCAAGACAGGCTCTTG

TAATCT 3'

AGGG 3'

37

720 bp

520 bp

650 bp

550 bp

523 bp (WT)
563 bp (SET)

2.2

TAMOXIFEN ADMINISTRATION AND

CERULEIN-

INDUCED PANCREATITIS
Tamoxifen (Sigma-Aldrich, St. Louis, MO, #T5648) was prepared in ethanol (Commercial
Alcohols) and corn oil (Sigma-Aldrich, St. Louis, MO, #C8267) on the day of the first oral
gavage administration. Tamoxifen was re-suspended in 4 ml corn oil and each mouse
received one ml (2 mg/mouse/day) every other day over 5 days using a 1 ml syringe and a
gavage needle (20G 1’’x2.25mm, SIGMA, St. Louis, MO). Cre-recombinase efficiency
using this methodology is >95% (Johnson et al., 2012).
Cerulein (MedChemExpress, London, UK, #FI-6934) was freshly prepared from powder
to reach a final concentration of 10 g/ml. Stock cerulein was stored at -20 C. 15 and 17
days after the first dose of tamoxifen, mice received eight hourly intraperitoneal injections
of cerulein (50 g/kg body weight in saline) to induce acute pancreatic injury (Carrière et
al., 2009). Control mice received a similar volume of 0.9% saline. Mice were weighed
every other day to monitor weight changes and health until sacrificed for the downstream
experiments.

2.3

TISSUE FIXATION AND HISTOLOGY

Mice were sacrificed five weeks after the first cerulein injection. The complete pancreas
was immediately harvested from each mouse and weighed. The head and tail of the
pancreas were placed in tissue cassettes and fixed in 4% formaldehyde for at least 24 hours
at 4 C. Tissues were rinsed in phosphate buffered saline (PBS) post fixation before being
dehydrated and embedded in paraffin blocks. Tissue blocks were sectioned at 5 μm
thickness on a Microtome (ThermoFisher Scientific, Waltham, MA), and 2-4 sections were
mounted onto glass microscope slides to prepare for use in the downstream staining.
Tissue sections were stained using several histological techniques including hematoxylin
and eosin stain (H&E), Periodic acid–Schiff (PAS), Alcian Blue stain (AB), and picrosirius
red stain. For all staining methods, tissue sections were de-waxed in xylene (3 x 5 min) and
rehydrated in a series of ethanol (100% ethanol 2 x 2 min, 90% ethanol 2 x min, 70%
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ethanol 2 x 2 min) followed by tap water for 5 min and distilled water for 1 min. After
staining, sections were dehydrated in 70% ethanol (2 x 30 sec), 90% ethanol for 1 minute,
100% ethanol (2 x 3 min), and xylene (3 x 5 min). Sections were coverslipped with
permount (ThermoFisher Scientific, Waltham, MA, #SP15500) and stored in a slide box
at room temperature for the downstream histological analysis.
To assess general histology of mouse pancreatic tissues, sections were subjected to H&E
staining. Sections were immersed in CAT Hematoxylin (Biocare Medical, #CATHE-M)
for 2 minutes and then washed in running tap water for 30 seconds. Sections were placed
in freshly filtered Tacha’s Bluing Solution (Biocare Medical, #HTBLU-M) for 30 seconds
followed by running tap water for 10 minutes. Finally, sections were dipped in freshly
filtered Eosin Y three times, immediately followed by dehydration and mounting. Whole
slide scanning and analysis was performed using the Aperio ScanScope (Leica Biosystems
Imaging Inc.). Pancreatic lesions were identified and graded based on the extent of acinar
cell differentiation, nuclear irregularities, and tissue fibrosis. Scoring of tissue damage such
as ADM, PanIN, inflammation and fibrosis was done by Dr. Liena Zhao. The percentage
of lesion area verses total tissue area was quantified using Aperio ImageScope software
(Leica Biosystems Imaging Inc.). For each genotype, slides obtained from 5-7 different
samples that contain the head and tail of the pancreas were assessed, and 10-15
representative images were taken from each sample using a Leica Microscope (Leica
Microscope DM5500B, Leica Microsystems, Wetzlar, Germany).
To measure the frequency and grade of preneoplastic lesions, tissue sections were stained
using standard Alcian Blue (AB) stain (Abcam Inc., Cambridge, UK, ab150662) for the
assessment of acidic mucins. Deparaffinized slides were incubated in acetic acid for 3
minutes and then in Alcian Blue pH 2.5 solution (Abcam Inc., Cambridge, UK, ab150662)
for 30 minutes at room temperature. After a few washes, sections were stained in Nuclear
Fast Red Solution (Abcam Inc., Cambridge, UK, ab150662) for 5 minutes. To detect
glycogen deposits in mucinous structure, Periodic Acid Schiff (PAS) staining (SigmaAldrish Inc., St. Louis, MO, #3952) was performed. For each genotype, 5 slides from
different samples that contain the head and tail of pancreas were stained. The positive
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staining lesions (blue for AB and red for PAS) were identified and quantified as a percent
of the total amount of lesions using ImageJ (National Institutes of Health, Maryland, USA).

2.4

IMMUNOHISTOCHEMISTRY

After de-paraffin and rehydration, tissue sections were incubated in antigen retrieval buffer
(100X citrate buffer pH 6.0) and put in a steamer for 45 minutes. Sections were cooled to
room temperature for 20 minutes. Sections were immersed in 3% H2O2 in methanol to
remove endogenous peroxidase activity followed by incubation in cell permeation reagent
(0.2% Triton-100 in PBS) for 12 minutes and washing in phosphate-buffered saline/tween
(PBST) (0.2% Tween-20 in PBS) for 5 minutes. To prevent non-specific binding of
antibodies to the tissue, sections were incubated in blocking solution (1.5% sheep serum in
PBS) for 1 hour at room temperature in a wet chamber. Sections were incubated in primary
antibodies diluted at recommended ratio in blocking solution overnight at 4 C. Table 2.2
shows information about antibodies used and corresponding dilution ratio, sources, and
species. On the second day, sections were incubated in biotinylated secondary antibody
(diluted 1:200 in blocking solution) for 30 minutes at room temperature followed by
washing in PBST for 6 minutes and PBS for 4X 6 minutes. IHC was developed using
VECTASTAIN rabbit ABC staining kit and DAB peroxidase substrate (Vector
Laboratories, SK-4105).
Analysis of acinar cell dedifferentiation and transdifferentiation was performed using
ImageJ. The expression of biomarker of acinar cells (amylase) and duct cells (CK19) was
visualized as brown stain in histologically relevant area of mouse pancreatic tissues.
Quantification of DAB signals was done using the threshold method in ImageJ, which can
selectively calculate the brown signal as the percent of total tissue area by adjusting the
threshold. The extent of immune cell infiltration in the stromal area was determined using
the Aperio ImageScope software. Positive immune cells were manually counted and were
divided by the total lesion area. Whole tissue images and representative images (10-15
images obtained per sample) of the lesion area were obtained with the Aperio ScanScope
and Leica Microscope, respectively.
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Table 2.2 Antibodies used for IHC

Antibody

Species

Source

Catalog #

Dilution

CK19

Rabbit

Abcam

Ab15463

1:200

AMYLASE

Rabbit

Cell Signaling

4017

1:400

CD3

Rabbit

BD Biosciences

560591

1:200

CD8

Rabbit

ThermoFisher

98941

1:200

F4/80

Rabbit

Abcam

Ab111101

1:100

VIMENTIN

Rabbit

Cell Signaling

5741S

1:400

-SMA

Rabbit

Cell Signaling

19245

1:200

C3

Rabbit

ThermoFisher

ab111101

1:200
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2.5

ACINAR CELL CULTURE

Mice of each genotype, WT, Ezh2SET, KRASG12D, KRASG12DEzh2SET were sacrificed three
weeks after the first tamoxifen injection, and the pancreas was harvested and washed in
~10 ml of 1xPBS in a 15 ml falcon tube on ice. 1 ml of collagenase (1 mg/ml) and ~50 ml
of HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer was pre-warmed
to 37 C in a shaking water bath. Pancreatic tissues were transferred into a clean weigh
boat without solution. Tissues were injected with 1 ml collagenase using a 1 ml syringe
and 25- or 27-gauge needle, then immediately incubated in collagenase solution in 2 ml
tubes in 37oC shaking at 75 rpm for 12 minutes. Then tissues were transferred to 50 ml
tubes with 6-7 ml DMEM (Dulbecco's Modified Eagle Medium) and vigorously
resuspended to break up clumps of tissue into cells. Once clumps were sufficiently
dispersed and the solution was cloudy, cell suspensions were gently pipetted through a prewetted 70 um nylon mesh into a 50 ml falcon tube. Cells were centrifuged at 200g in
centrifuge (Eppendorf Canada, #5804R) for 1 minute and collected at bottom of tube.
Acinar cells were incubated in 48-well plates with freshly made acinar cell culture media
containing DMEM/ F12 Medium (Gibco, Invitrogen, Carlsbad, CA), 10% fetal bovine
serum (FBS), 0.04 mg/ml Soybean Trypsin Inhibitor (STI), and 0.1% dexamethasone.
Collagen type I and acinar cell culture media were mixed at a proportion of 1:1, with a
small volume (1:20 dilution) of 0.25 M NaOH to adjust the pH. Approximately 2500 acinar
cells were mixed with 100 ul of the mixture and were plated at the bottom of the well. Cells
were monitored at a daily basis and media was changed every other day.

2.6

RNA ISOLATION AND RNA -SEQ ANALYSIS

RNA was extracted from mouse pancreatic tissues using Trizol (Invitrogen) following Pure
link kit (Invitrogen) manufacturer’s protocol. To obtain RNA, tissue samples were
mechanically homogenized immediately following dissection. Three replicates were
obtained for KRASG12D and KRASG12DEzh2SET groups. RNA from each sample was
subjected to paired-end sequencing with Illumina TruSeq Stranded Total RNA kit.
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To perform RNA-seq analysis, reads were aligned to the mouse reference genome mm10
(GRCm38) and sorted by coordinate using STAR v2.7.9a (Dobin et al., 2013). Gene counts
were generated using featureCounts function of the Subread v2.0.3 aligner (Liao et al.,
2014). Differential expression analysis was performed using edgeR v3.32.1 (Robinson et
al., 2010; McCarthy et al., 2012) R Studio package. A 0.05 adjusted p value cut off was
used. Pathway analyses was performed using clusterProfiler v3.18.1 R package (Yu, 2012
and 2018) with a 0.05 adjusted p value cut off.

2.7

STATISTICAL ANALYSIS

Statistical analysis of data and graph generation were done using GraphPad Prism 6
software (Graphpad La Jolla, USA). Comparisons between groups and within groups were
performed using one-way Anova with a tukey’s post hoc test and unpaired two-tailed t-test.
Data was expressed as mean ± standard error of mean (SEM), with individual values and
error bar presented. Statistical significance level was set at p < 0.05.
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3

CHAPTER 3: RESULTS
3.1

The absence of EZH2 in the KRASG12D context does not alter

the size of premalignant lesions in mice after acute pancreatitis
To determine whether Ezh2 deletion promotes KRAS-driven initiation of PDAC following
acute pancreatic injury, a cohort of wild type, Ezh2DSET, KRASG12D, and KRASG12DEzh2DSET
mice were treated with either saline (control) or cerulein every other day over three days
to induce acute pancreatitis (Figure 2.1). The body weight of mice was monitored and
evaluated three times a week after the first day of injections. A sharp reduction in body
weight was observed in all mice post treatment, with a gradual recovery starting at day 5.
CIP (cerulein induced pancreatitis)-treated mice showed significant weight loss (P<0.05)
compared to the saline group from Day 3 to Day 10, but no significant differences (P>0.05)
in the percent changes in body weight were seen between different genotypes (Figure
3.1A). The overall body weight change (i.e., comparing final to starting weights) were not
significantly different (P>0.05) between all the genotypes or between saline- and CIPtreated groups (Figure 3.1B). Mice were killed 35 days after the first cerulein injection and
pancreatic tissues harvested and weighed. No statistical differences (P>0.05) were found
in the pancreas to body weight ratios between saline- and cerulein-treated mice or between
genotypes (Figure 3.1C). Representative images of the pancreas of CIP-treated mice were
obtained upon dissection. The pancreatic tissues all appeared as relatively flat and pinkish
white in color (Figure 3.1D). Comparisons of the gross pancreatic morphology revealed
no obvious differences among genotypes.
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G12D

KRAS

G12D

SET

Ezh2

Figure 3.1 KRASG12D and KRASG12DEzh2SET mice show no significant difference in
body weight gain and pancreatic/body weight ratio compared to WT and Ezh2SET
mice after acute pancreatic injury. (A) Cerulein-treated mice (CIP; n=25, includes all
genotypes) showed significant loss in body weight compared to saline-treated groups (n=9;
*P<0.05, **P<0.0001; a repeated measures ANOVA with a Tukey’s post hoc test was
performed) from day 3-10. No statistical difference in final body weight change (B) and
pancreatic/body weight ratio (C) was observed between genotypes or between cerulein and
saline group (P>0.05). The error bar represent mean ± SEM. (D) Gross morphology of
pancreas in situ. The forceps pointed out the pancreas.

46

To examine the level of tissue damage in wild-type (WT), Ezh2SET, KRASG12D, and
KRASG12D Ezh2SET pancreatic tissues, portions of both the head and the tail of the pancreas
were embedded and subjected to histological analysis. The assessment of general
morphology of pancreatic tissues by H&E staining revealed significantly more PanIN
lesions and dense dysplastic stroma in cerulein-treated KRASG12D and KRASG12DEzh2DSET
mice compared to saline-treated groups or cerulein-treated WT and Ezh2DSET tissues
(Figure 3.2A). Interestingly, a large fraction of PanIN lesions is found predominately
located in one part of the pancreas, while the other part is relatively normal acinar tissue,
which is consistent with previous finding that most PDAC develops from the head of the
pancreas (Corbo et al., 2012). Saline-treated KRASG12D and KRASG12DEzh2SET mice
showed only occasional lesions in the pancreas while WT and Ezh2SET pancreas did not.
Quantification of the lesion area indicated KRASG12D and KRASG12D Ezh2SET tissues
contained significantly more lesion area, including desmoplastic stroma, than WT and
Ezh2SET tissues (which showed no PanIN lesions or ADM; Figure 3.2C) following
cerulein treatment. The extent of pancreatic injury varied among KRASG12D and
KRASG12DEzh2SET mice. KRASG12D tissues showed more variation in the percentage of
lesion size, with some mice showing occasional focal lesions (1.69% of total pancreatic
tissue area) to large majority of the tissue showing lesions (84.18% of total pancreatic tissue
area). KRASG12D Ezh2SET tissues showed more consistent lesions to total tissue size ratio.
However, KRASG12DEzh2SET mice showed no differences in the number or extent of
PanINs in terms of the size and the area of metaplastic lesions in the pancreas compared to
age matched KRASG12D mice (Figure 3.2C). The average lesion to total tissue area ratio
was 26.92 ± 10.96% SEM for CIP-treated KRASG12D tissues (n=7), and 15.04 ± 3.51%
SEM for KRASG12DEzh2SET tissues (n=9), which are not statistically different (P>0.05)
(Figure 3.2B).
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Figure 3.2 The absence of EZH2 does not alter PanIN lesion size. (A) Representative
H&E displays occurrence of pancreatic lesions in WT, Ezh2SET, KRASG12D, and
KRASG12DEzh2SET mice with (n=7, 7, 7, and 9, respectively) or without cerulein treatment
(n=4, 1, 2, and 2, respectively) five weeks after initial cerulein injections. Magnification
bar = 100 μm. (B) Whole slide H&E images showed regionalization of PanIN lesions
(indicated by black arrows). Magnification bar = 2 mm. (C) There were no significant
differences in the percentage of lesion area between KRASG12D and KRASG12DEzh2SET
tissues cerulein treatment (P>0.05). The error bars represent mean ± SEM. Significantly
increased levels of tissue damage were observed between saline- and CIP-treated groups
in KRASG12D and KRASG12DEzh2SET tissues. A two-way ANOVA with a Tukey’s post hoc
test was performed.
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Atrophy of pancreatic acini, lobulated proliferation of ducts with associated stromal
fibrosis, and chronic inflammation were observed in both KRASG12D and KRASG12D
Ezh2SET tissues treated with cerulein. Cells within some precursor lesions exhibited basally
located nuclei and abundant mucinous cytoplasm, suggesting the presence of PanIN with
low-grade dysplasia, such as PanIN-1 and PanIN-2. High-grade dysplasia or invasive
malignancy was rarely seen in both genotypes (Figure 3.3).
To examine ADM in response to acute pancreatic injury, IHC was performed for the duct
cell marker, cytokeratin 19 (CK19), and the acinar cell marker, amylase in cerulein-treated
mice (Figure 3.4). KRASG12D and KRASG12DEzh2SET pancreata showed a significant
decrease in amylase+ to CK19+ tissue compared to WT and Ezh2SET pancreata, indicating
gain of ductal identity in both genotypes following injury (Figure 3.4A). In addition,
expression of ductal marker CK19 was observed within many acinar cells of Ezh2SET
tissues, while amylase was observed in PanIN lesions, supporting an acinar origin for
PanINs (Liu et al., 2016). However, the ratio of amylase+/CK19+ tissue was comparable
(P>0.05) between KRASG12D (27.08±2.04% SEM, n=7) and KRASG12DEzh2SET pancreata
(39.21±5.37% SEM, n=7) (Figure 3.4B). This suggests that acinar cell de-differentiation
to duct cells occurs to the same extent in KRASG12D and KRASG12D Ezh2SET tissues
following cerulein-induced injury. Interestingly, Ezh2 deletion does not limit the ability of
acinar cells to regenerate in the pancreas after injury with or without the effects of
oncogenic KRAS.
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Figure 3.3 Both KRASG12D and KRASG12DEzh2SET mice show low grade PanIN lesions
after acute pancreatic injury. Representative high magnification H&E images showing
histological grading of pancreatic lesions in WT, Ezh2SET, KRASG12D, and
KRASG12DEzh2SET mice five weeks post-cerulein treatment. The presence of ADM
(indicated by stars) and PanIN-1 lesions (indicated by arrows) were identified in both
KRASG12D and KRASG12DEzh2SET tissues. Magnification bar = 100 μm.
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Figure 3.4 The loss of EZH2 does not affect the amount of acinar/duct tissue. (A)
Representative images of IHC staining for CK19 and amylase in WT, Ezh2SET, KRASG12D,
and KRASG12DEzh2SET mice following cerulein treatment. Black arrows indicate CK19+
lesions, and blue arrows indicate amylase+ acini. Magnification bar = 100 μm. (B) No
significant difference was found in the CK19/amylase ratio between KRASG12D, and
KRASG12DEzh2SET mice 5 weeks after the last cerulein injection (P>0.05). An unpaired
two-tailed t test was performed.
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3.2

Mice lacking EZH2 methyltransferase activity showed an

increased number of higher grade PanIN lesions in the context of
KRASG12D activation
Although initial analysis did not show significant differences in the level of KRASG12D induced PanIN lesions in the absence of EZH2, it is possible that the role of EZH2 in the
progression of PanIN lesions is more subtle. To address this possibility, the severity of
lesions was examined using two different histological staining methods, Alcian Blue and
PAS stain. Alcian Blue stain detects acidic mucin production, which is normally associated
with enhanced tumorigenicity and invasiveness of reactive PanIN lesions (Saitou et al.,
2005). PAS stains glycogen and is used to accurately measure the extent of PanIN lesions
as glycogen deposits are evidence of cancerous cells. Alcian Blue stain revealed no staining
in CIP-treated WT or Ezh2SET mice or in saline treated groups. However, by week five
following induced injury, a significantly greater (P<0.005) percentage of Alcian Blue+
lesions were detected in CIP-treated KRASG12DEzh2SET mice (55.14 ± 3.26% SEM, n=9)
compared to KRASG12D mice (34.14 ± 2.90% SEM, n=7) (Figure 3.5A-C), suggesting
KRASG12DEzh2SET mice treated with cerulein more frequently developed higher grade
PanIN lesion compared to KRASG12D mice. This finding was supported by PAS staining,
showed significantly fewer (P<0.05) glycogen+ PanIN lesions (Figure 3.6A-C) in
KRASG12D mice (39.86% ± 6.15% SEM) compared to KRASG12DEzh2SET mice (58.57% ±
3.05% SEM) (Figure 3.6B). No accumulation of glycogen was detected in saline-treated
KRASG12D and KRASG12DEzh2SET mice, as well as in CIP-treated control groups. In
summary, these combined results show KRASG12DEzh2SET tissues have more progression
PanIN lesions 5 weeks after initial cerulein injections compared to KRASG12D tissues, even
though the lesion area percentages between two genotypes were comparable.
Finally, the level of collagen in CIP- and saline-treated mouse pancreas was visualized
using picrosirius red staining. Positive stain revealed the presence of collagen deposition
in CIP-treated KRASG12D and KRASG12DEzh2SET mice, specifically in the desmoplastic
stromal area (Figure 3.7). In contrast, much less collagen accumulation was observed in
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saline treated KRASG12D and KRASG12DEzh2SET tissues. WT and Ezh2SET tissues showed
little collagen expression around lobes, large vessels, and islets. KRASG12D Ezh2SET tissues
showed more extensive positive staining compared to KRASG12D tissues, which would
indicate a higher degree of pancreatic fibrosis in the presence of oncogenic KRASG12D and
pancreatic injury, and that deletion of Ezh2 could lead to more accumulation of dense
collagen fibers in the stroma. Collagen quantification was not performed as sufficient
sample sizes were not achieved.
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Figure 3.5 KRASG12DEzh2SET tissue shows increased expression of acidic mucins. (A)
Representative alcian blue images shows an increase in acidic mucins in the absence of
Ezh2 in the context of KRASG12D following cerulein treatment. Black arrows point out the
positive stain. Magnification bar = 100 μm. (B) Low magnification images show a more
extensive area of analysis (indicated by black arrows). Magnification bar = 100 μm. (C)
Quantification of representative images confirms a significant increase (n=7 for both;
**P<0.005) in the percentage of AB+ lesions in KRASG12D Ezh2SET mice 5 weeks after the
last cerulein injection compared to KRASG12D mice. Mean±SEM is shown. A two-tailed
unpaired t test was performed.
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Figure 3.6 KRASG12DEzh2SET tissue shows increased PAS+ stain. (A) Representative
PAS images show an increase in PAS+ stain in the absence of Ezh2 in the context of
KRASG12D following cerulein treatment. Black arrows point out the positive stain.
Magnification bar = 100 μm. (B) Low magnification images show a more extensive area
of analysis (indicated by black arrows). (indicated by black arrows). Magnification bar =
100 μm. (C) Quantification of representative images confirms a significant increase in the
percentage of PAS+ lesions in KRASG12DEzh2SET mice 5 weeks after the last cerulein
injection (n=7 for both; P<0.05). A two-tailed unpaired t test was performed.
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Figure 3.7

KRASG12D and KRASG12DEzh2SET tissues show increased collagen

deposition in the stromal area. Representative images showing Picrosirius red staining
of pancreatic tissues from each group. Black arrows indicate fibrosis. Magnification bar =
100 μm.
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3.3

Ezh2 deletion alters the molecular response to KRASG12D

Next, I examined the effects of Ezh2 deletion on the molecular profile of acinar cells with
or without KRASG12D activation. WT, Ezh2SET, KRASG12D, and KRASG12DEzh2SET mice of
2-4 months old were administered with tamoxifen to specifically activate creERT, which
leads to oncogenic KRASG12D activation or Ezh2 deletion. Twenty-two days following
tamoxifen treatment, mice of all genotypes were sacrificed. The extent of tissue damage
was examined by histological stain. Low power images of H&E staining revealed no
obvious difference in general pancreas morphology among all genotypes. Most of the
sections showed normal exocrine pancreas - a large number of acini, occasional fat cells,
and the islets of Langerhans can be recognized in the tissue sections. No detectable
pancreatic lesions are found in all genotypes (Figure 3.8A).
RNA-seq was performed on RNA isolated form whole pancreatic tissues from 22 days
after tamoxifen gavage without cerulein-induced pancreatic injury. This time point was
chosen because no obvious morphological differences were shown, and the cell makeup of
the pancreas was relatively similar among genotypes. RNA-seq analysis of KRASG12D and
KRASG12DEzh2SET mouse acinar cells revealed 315 genes significantly dysregulated in the
absence of EZH2, with 237 genes upregulated and 78 genes downregulated (Figure 3.8B).
To examine the molecular mechanisms involved in the loss of Ezh2, pathway analysis was
performed with these genes using The Database for Annotation, Visualization and
Integrated Discovery (DAVID) Bioinformatics Resources (2021 update) to investigate the
functions of the selected 96 genes. Gene Ontology (GO) enrichment analysis identified 49
pathways significantly dysregulated between KRASG12D and KRASG12DEzh2SET genotypes.
The results were ranked by the enrichment score and the top-ranked 20 signaling pathways
are shown in Figure 3.8C. Many of the top-ranked pathways are related to inflammatory
and immune responses, including the top five enriched pathways: adaptive immune
response (GO:0002250), antigen processing and presentation of exogenous peptide antigen
(GO:0002478), adaptive immune response based on somatic recombination of immune
receptors built from immunoglobulin superfamily domains (GO:0002460), antigen
processing and presentation of exogenous peptide antigen via MHC class II (GO:0019886),
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and antigen processing and presentation of exogenous antigen (GO:0019884) (Figure
3.8C).
Among the differentially expressed genes, the C3 gene appeared in the top five pathways
dysregulated in the absence of EZH2. RNA-seq data noted indicated significantly higher
levels of C3 expression in KRASG12DEzh2SET compared to KRASG12D tissues. IHC staining
for C3 in mouse pancreas indicated that C3 is solely expressed in KRASG12DEzh2SET tissues,
specifically in columnar epithelial cells within the lesion area, while no positive signals
were found in KRASG12D lesions. To be noted that the gene expression analysis was done
in mouse tissues 22 days after tamoxifen without cerulein-induced injury, while
histological analysis of C3 was done in tissues that were injured five weeks before
dissection (Fig 3.9B).
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Figure 3.8 The loss of Ezh2 leads to dysregulation of inflammatory response pathways
in the absence of significant damage to the pancreas. (A) H&E histology of WT,
Ezh2SET, KRASG12D, and KRASG12DEzh2SET pancreatic tissues. Magnification bar = 100
μm. (B) Volcano plot with log2 FC indicating the mean expression level for each gene.
Each dot represents a gene. Black dots represent no significant differentially expressed
genes between KRASG12D and KRASG12DEzh2SET groups. Blue and red dots represent
significant differentially expressed genes (blue is padj< 0.05, red is padj<0.05 and
Log2foldchange >2; n=3 for each group). (C) GO pathway analysis of the differentially
expressed

genes

(padj

<0.05,

Log2foldchange

>2)

between

KRASG12D

and

KRASG12DEzh2SET groups (n=3 for each group). Figure 3.8B and C courtesy of Fatemeh
Mousavi.
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Figure 3.9 The absence of EZH2 affects the expression of complement C3 in PanIN
cells. Representative high (right) and low (left) power IHC images showed that the
expression of complement C3 was observed in the columnar epithelial cells of
KRASG12DEzh2SET tissue at week five post CIP. WT, Ezh2SET and KRASG12D does not
show positive signal for C3 in PanIN cells. in Black arrows point out C3-positive cells.
Magnification bar = 100 μm.
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3.4

Ezh2 deletion in the context of KRASG12D induces tumor

microenvironment modulation in PanIN progression
Previous results indicated that loss of EZH2 activity enhanced PanIN lesion progression in
the presence of KRASG12D. The analysis of RNA-seq in KRASG12DEzh2SET and KRASG12D
suggested the absence of EZH2 leads to dysregulation of multiple inflammatory pathways.
To confirm the relationship between Ezh2 deletion and the immune response in the
pancreas, I examined the presence of immune cells and cancer-associated fibroblasts
(CAFs) in the tumor microenvironment of CIP-treated mice by IHC staining. Infiltration
of cytotoxic T lymphocytes was detected by IHC for CD8, while CD3 measures total
intratumoral T lymphocytes (Andrew et al., 2016). The presence of macrophages was
marked by the expression of F4/80. High expression of vimentin and aSMA was used as
markers for pancreatic CAF (panCAF) and myCAF, respectively.
I first looked at the infiltration of cytotoxic CD8+ T cells. As expected, CIP-treated WT
and Ezh2SET mice showed no accumulation of CD8 (Figure 3.10). In CIP-treated
KRASG12DEzh2SET and KRASG12D mice, however, CD8+ cytotoxic T lymphocytes were
detected in the desmoplastic stroma, suggesting the occurrence of inflammation in the TME.
Although the difference is not significant (P=0.069), KRASG12D tissues showed a trend
towards increased numbers of CD8+ cells (26.91 ± 3.57 cell/mm2 SEM, n=5) compared to
KRASG12DEzh2SET tissues (14.30 ± 4.75 cell/mm2 SEM, n=5) (Figure 3.10). Similar to
CD8, IHC staining for CD3 revealed negligible T cells in KRASG12D Ezh2SET and
KRASG12D mice in response to cerulein-induced injury, while KRASG12DEzh2SET and
KRASG12D mice showed T cell infiltration in the TME. The average density of CD3+ T
cells was slightly, but not significantly (P>0.05), higher in KRASG12D (153.8 ± 26.08
cell/mm2 SEM, n=5) compared to KRASG12DEzh2SET tissues (113.3 ± 18.99 cell/mm2 SEM,
n=5) (Figure 3.11). Next, I tracked macrophage infiltration in all four genotypes by
staining for F4/80. IHC revealed no infiltration of macrophages in pancreatic tissues of
CIP-treated WT and Ezh2SET mice. There was a significantly (P<0.005) increased
infiltration of F4/80 positive macrophages in the stromal area of KRASG12D (1.33 ± 0.34%
SEM, n=5) compared to KRASG12DEzh2SET tissues (0.08 ± 0.03% SEM, n=5) (Figure
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3.12). The amount of macrophage recruitment in the stroma largely varies in KRASG12D
samples, which essentially ranges from 0.20% to 2.25% positive stain verses the total
lesion area. These results suggested that the absence of EZH2 in the presence of oncogenic
KRASG12D slightly reduces the recruitment of T lymphocytes and macrophages into the
TME surrounding PanIN lesions.
To determine whether other non-acinar cell types of the TME are affected by the deletion
of EZH2 in the KRASG12D context, I examined if the absence of EZH2 caused altered
accumulation of CAFs in the TME of WT, Ezh2SET, Mist1creERT/+KRASG12D and
KRASG12DEzh2SET mice. myCAFs, as marked by aSMA positive signals, was comparably
abundant in both KRASG12D and KRASG12DEzh2SET tissues, while negligible amount of
myCAF accumulation can be detected in WT and Mist1creERT/+EZH2SET tissues (Fig. 3.13).
MyCAFs were predominantly located at the center of the injured area adjacent to PanIN
lesions, and not at the peripheral edges of the TME. Similar analysis for the marker of
panCAF, vimentin, revealed no accumulation in WT and Ezh2SET, and high amounts of
expression in KRASG12D and KRASG12DEzh2SET mice. No obvious differences in terms of
the levels of myCAF and panCAF accumulation was detected between KRASG12D and
KRASG12DEzh2SET tissues. Combined, these data suggest the loss of EZH2 in the context
of oncogenic KRASG12D may play a role in the modulation of the TME, especially the
recruitment of immune cells. This difference may be correlated with the more progressive
phenotype of PanIN lesions.
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Figure 3.10 Infiltration of CD8+ lymphocytes after CIP show a decreased trend in the
absence of EZH2. Representative high (right) and low (left) power IHC images showed
that the number of CD8+ lymphocytes marker was lower in KRASG12DEzh2SET tissues
compared to KRASG12D. CD8 infiltration was not observed in WT and Ezh2SET tissues.
Black arrow pointed out the positive stain. Magnification bar = 100 μm. (B) Quantification
of CD3 confirmed a trend that was not statistically significant in CD8+ cells in KRASG12D
tissues post injury (cells/mm2 mean ± SEM, n = 5; P=0.0690; unpaired two-tail student’s t
test was performed)
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Figure 3.11 EZH2 deletion does not affect the total amount of lymphocyte infiltration
into the pancreas the stroma. Representative high (right) and low (left) power IHC
images showed that the number of CD3+ lymphocytes marker was not statistically different
between KRASG12D tissues compared to KRASG12DEzh2SET. Black arrows indicate positive
stain. Magnification bar = 100. (B) Quantification of CD3+ cells showed higher numbers
in KRASG12D tissue but was not statistically significant that the number of CD3+ cells in
KRASG12D tissue post injury (cells/mm2 mean ± SEM; n = 5; P>0.05; unpaired two-tail
student’s t test was performed).
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Figure 3.12 EZH2 deletion reduces macrophage infiltration into the stroma. (A)
Representative high (right) and low (left) power IHC images of macrophage marker F4/80
showed

no

accumulation

of

macrophages

in

WT

and

Ezh2SET

pancreas.

KRASG12DEzh2SET showed remarkably more positive stain compared to KRASG12D tissue
samples. Black arrows indicate the positive stain. Magnification bar = 100 μm. (B) The
quantification of F4/80 confirmed a significantly increased macrophage accumulation in
KRASG12D tissues post injury (% mean ± SEM; n = 5; **P<0.005; unpaired two-tail
student’s t test was performed).
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Figure 3.13 EZH2 deletion does not alter the total number of myCAFs in the tumor
microenvironment. Representative high (right) and low (left) power IHC images of
myCAF marker smooth muscle actin in KRASG12DEzh2SET and KRASG12D tissue samples
showed no overall difference in the expression level. Magnification bar = 100 μm.
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Figure 3.14 EZH2 deletion does not alter the total amount of CAFs in the tumor
microenvironment. Representative high (right) and low (left) power IHC images of
panCAF marker vimentin in KRASG12DEzh2SET and KRASG12D tissue samples showed no
overall difference in the expression level. Magnification bar = 100 μm.
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3.5

The loss of EZH2 does not affect KRAS-mediated ADM in cell

culture
Based on in vivo experiments, the loss of EZH2 appeared to promote the progression of
PDAC in the KRASG12D context and reduce immune cell recruitment into the TME. To
determine if acinar expression of KRASG12D along with EZH2 deletion increased ADM
without the effects of the TME, acinar cells from WT, Ezh2SET, KRASG12D and KRASG12D
Ezh2SET pancreata were isolated 22 days after tamoxifen injections and embedded in 3D
collagen culture. Acinar cells were maintained and monitored for five days in the culture
post-isolation. The development of cysts (putative ADM) was measured by calculating the
number of cysts formed as a percentage of total clusters of cells, which represent individual
acini. The size of ADM was measured for 10-20 clusters. WT and Ezh2SET cells formed
cysts in less than 10% of the total acinar clusters by day 2, while KRASG12D and
KRASG12DEzh2SET acinar cells clusters formed cysts in the majority of clusters examined,
reaching up to 95% of the total cell clusters. From day 2 to day 5, significantly more cysts
were formed in KRASG12D and KRASG12DEzh2SET cultures than in WT and Ezh2SET cells
(P<0.05) (Figure 3.15A-B). However, from the third experimental day, ADM did not
change in size and appeared to undergo apoptosis or necrosis, leading to a decrease in the
percentage of cysts observed (Figure 3.15A-B). Analysis of cyst formation in culture
showed no significant differences between KRASG12D and KRASG12DEzh2SET acini,
suggesting EZH2 does not overtly affect cyst formation, consistent with in vivo data. Next,
I examine changes in the size of the cysts throughout experimental days. Morphologically,
cysts developed from WT, Ezh2SET, KRASG12D and KRASG12D Ezh2SET all increased their
size to different extent during growth in the collagen culture in the beginning. Started from
the second day in culture, KRASG12D and KRASG12D Ezh2SET acinar cell clusters formed
cysts that became spherical and exhibited hollow lumens. These cysts reached a final size
of ~40,000 m2, while only ~5,000 m2 in WT and Ezh2SET cultures. (Figure 3.15C). The
percentage and size of cysts was comparable between KRASG12D and KRASG12DEzh2SET
cells, indicating that knockout of Ezh2 alone did not affect the growth of KRAS-mediated
ADM in culture in an overt fashion.
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DAY 5

Figure 3.15 Loss of EZH2 does not affect the amount of KRASG12D-mediated ADM.
(A) Phase contrast microscopy of acinar cells derived from WT, EZH2ΔSET, KRASG12D,
and KRASG12DEZH2ΔSET mice two weeks after tamoxifen administration. Images were
taken one, three, and five days in culture. White arrows indicate the presence of cysts
(putative ADM). Magnification bar = 100 μm. (B) Quantification of the percentage of
ADM (% mean ± SEM; n=3) formation showed significant differences between cells with
and without KRASG12D activation (P<0.05) from day 2-5, but no significant difference
found between cells with and without EZH2 (P>0.05). (C) Quantification of the size of
ADM (mm2 mean ± SD; n=3) from day 1 to day 5. Significant difference was observed
between cells with and without KRASG12D activation (P<0.05). No significant difference
was found between cells with and without EZH2 (P>0.05). A repeated measure Two-way
ANOVA with a Tukey’s Post hoc test was performed.
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4

CHAPTER 4: DISCUSSION
4.1

Conclusions

In this thesis, I examined the role of EZH2 in KRASG12D-driven PDAC in response to acute
pancreatitis and in KRASG12D-mediated ADM formation in ex vivo cultures. I showed that
the absence of EZH2 in adult acinar cells resulted in more progressive PanIN lesions
following pancreatic injury and KRASG12D activation. RNA-seq analysis showed loss of
EZH2 altered the molecular response to KRASG12D in mouse pancreatic acinar cells, but
only a small number of genes were differentially expressed between acinar cells expressing
EZH2 or not expressing EZH2. The majority of significantly affected genes were
associated with inflammatory signaling pathways. These findings were supported in the
context of KRASG12D expression in the presence of pancreatic injury. The absence of EZH2
methyltransferase activity resulted in reduced immune cell infiltration in the tumor
microenvironment, especially macrophages. Interestingly, EZH2 deletion did not affect the
development of KRAS-driven ADM in cell culture, as the rate of ADM formation and size
were unaffected by the absence of EZH2. These findings suggest the effects of EZH2 may
be through the tumor microenvironment. Taken together, these data suggest EZH2
modulates inflammatory infiltration and results in higher grade of PanIN lesions following
acute pancreatic injury. The findings highlight the potential of EZH2 as a direct therapeutic
target to prevent tumor growth in PDAC patients.

4.2

Overview

Despite extensive research efforts, PDAC continues to be a leading cause of death in
Canada due to the lack of early detection methods and effective treatments. The KRAS gene
is mutated in 95% of all PDAC cases (Guo et al., 2016) and plays a role in the initiation of
PDAC by promoting irreversible acinar-to-ductal metaplasia (ADM) process. This leads to
low-grade PanINs and increases the risk of further progressing to PDAC (Andrew et al.,
2020). Previous research showed the epigenetic regulator EZH2 played a key role in the
development of KRASG12D-driven PDAC. For example, Mallen St. Clair et al. (2012)
showed Ezh2 deletion in mouse embryos accelerated KRASG12D-mediated PDAC and
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prevented pancreatic regeneration. Conversely, Chen et al. (2017) found during late stages
of PDAC development, EZH2 deficiency reduced tumor expansion. Both human research
and studies on mouse models revealed high levels of EZH2 often correlated to more
aggressive and invasive PDAC phenotype and reduced sensitivity to KRAS oncogene (Kim
et al., 2015; Patil et al., 2020).
In this thesis, I specifically looked at the effects of Ezh2 deletion on KRAS-driven PDAC
progression in the context of acinar cells from adult transgenic mice and addressed the
hypothesis in early neoplasia in the pancreas before the development of invasive PDAC,
which is distinct from the other studies and is not well-addressed before.

4.3

EZH2 restricts the progression of KRASG12D-driven PDAC

following acute pancreatic injury without limiting PanIN lesion
expansion
A previous study from our lab that examined the effects of EZH2 deficiency in KRASmediated PDAC that developed spontaneously in adult mice revealed no significant
differences in morphological and histological changes in the pancreas. Conversely, EZH2
appeared to dramatically enhance KRAS-mediated ADM and PDAC when combined with
events that trigger acinar cell dedifferentiation such as Mist1 deficiency (Shi et al, 2013).
Therefore, the work presented in this study utilized methodology that induced acute
pancreatic injury, which increases the susceptibility to PDAC, five weeks prior to
histological analysis to investigate in detail whether EZH2 deletion affects the progression
of PDAC in the context of KRASG12D.
My results showed no evident histological changes in overall lesion formation, which
contradicts previous findings (Mallen St. Clair et al, 2012). The lesion size and level of
fibrosis of the tumor microenvironment was similar in the absence of EZH2 and
constitutive activation of KRASG12D, suggesting loss of EZH2 does not significantly
promote or restrict KRAS-driven PanIN lesion expansion in response to acute injury.
However, significantly more mucin+ PanIN lesions were observed in KRASG12DEzh2SET
tissues, suggesting more higher-grade lesions in KRASG12DEzh2SET compared to KRASG12D
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tissues. Similar to Mallen St. Clair et al. (2012) whose findings support a model that KRASmediated PDAC is accelerated by deletion of EZH2. In contradiction with that same study,
which demonstrated a vital role of EZH2 in tissue regeneration in response to pancreatic
injury (Mallen St. Clair et al., 2012), the loss of EZH2 alone without the effects of
oncogenic KRAS did not affect pancreatic regeneration and repair.
The contradictory findings may be explained by differences in the mouse models used and
distinct roles for EZH2 at different stages of PDAC progression. Our model focussed on
induced deletion of EZH2 and activation of KRASG12D in adult mice instead of mouse
embryos, which is a better predictor of PDAC in humans since most people accumulate
mutations and develop cancers later in life. Another explanation for the inconsistency is
that different Cre recombinase drivers were used in this project vs. previous studies. Most
studies utilize the Ptf1a locus as a Cre driver to induce genetic recombination specifically
in mouse pancreas, including constitutive KRASG12D activation and Ezh2 deletion. Since
Ptf1a is a crucial gene for pancreatic organogenesis and is expressed in pancreatic
multipotent pancreatic cells (MPCs) during development, it may lead to a recombined
allele in all cell types in mouse pancreas. However, Ptf1a expression is restricted to acinar
cells in adult mice (Kawaguchi et al., 2002). In my thesis, Mist1 was used as a driver gene
to induce acinar-specific deletion. While it is reported that Ptf1a and Mist1 are both
essential for maintaining mature acinar identity and restricting KRAS-mediated
tumorigenesis (Jiang et al., 2016), our preliminary lab data demonstrated a significant
difference in the progression of PanIN lesions between PK (Ptf1acreERT/+KRASG12D) and
MK (Mist1creERT/+KRASG12D) (unpublished data; Mousavi and Lau).
As previously mentioned, Mallen St. Clair et al. (2012) demonstrated the loss of EZH2
function promotes neoplastic progression during early stage of PDAC, while Chen et al.
(2017) stated at late stages of pancreatic regeneration after injury, the loss of EZH2 allows
acinar cell redifferentiation and pancreatic tissue recovery. Accumulating evidence
suggests EZH2 might have distinct roles at different stages of PDAC progression, and the
activation of KRAS oncogene may play a role in modulating the effects of EZH2 in a
temporal manner. Therefore, it is possible that the inconsistency between studies is due to
different experimental timing that reflect different outcomes, meaning that EZH2 caused
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more progressed PanIN lesions in the context of KRASG12D at the beginning, but trending
toward a decreased level of lesions at later stage.
Overall, my data suggest that EZH2 restricts KRAS-mediated early PanIN progression in
mouse models without limiting PanIN expansion, which raises the question of whether the
absence of EZH2 caused genetic alterations that can explain the more progressive
phenotype and what intracellular signalling pathways are involved.

4.4

EZH2 dysregulation affects inflammatory response pathways

in response to KRASG12D
EZH2 normally functions to suppress gene expression and transcriptional silencing of
genes mediated by aberrant EZH2 function has been implicated in cancer cell metastasis.
To understand how EZH2 deletion enhances PDAC progression, I examined RNA-seq
analysis 22 days after tamoxifen induction and see whether the absence of EZH2 altered
the molecular response to KRASG12D hyperactivation in mouse acinar cells without
cerulein-induced injury. RNA-seq analysis identified 315 genes that were differentially
expressed between KRASG12D and KRASG12DEzh2SET cells, at a time when there were no
phenotypic differences between the two lines. 237 genes were significantly upregulated
and 78 were significantly downregulated in KRASG12DEzh2SET relative to KRASG12D cells.
Consistent with the well-known role of EZH2 as an epigenetic suppressor, more genes
seemed to have increased expression levels in the absence of EZH2. GO analysis identified
five pathways specifically linked to immune related functions, suggesting an effect on the
TME. One immunity related pathway is the adaptive immune response pathway, which
predominantly involves the function of T lymphocytes (Slack, 2020). It is reported,
however, that EZH2 is overexpressed in many typical cancers and functions by suppressing
the activation of the adaptive immune response pathway (Zhao et al., 2016). This
specifically affects the anti-tumor effects of the cytotoxic or pro-inflammatory immune
response in the pancreas. Other affected pathways include leukocyte mediated immunity
pathway, negative regulation of immune system process, and lymphocyte mediated
immunity. These findings suggest the deletion of EZH2 alters many intrinsic, immune-
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related pathways that may affect the TME, which may explain the higher grade PanIN
lesions observed in KRASG12DEzh2SET mice.
The complement C3, one of the genes significantly differentially expressed between
KRASG12D and KRASG12DEzh2SET, is specifically studied in this project because it is
involved in most of the top ranked pathways. The C3 gene encodes the protein complement
component 3, which plays a key role in the complement system as part of the immune
response (Zhang et al., 2020). The complement system is a group of proteins that
collaborate to prevent and destroy foreign invaders and trigger inflammation. Previous
studies identified the prognostic role of complement C3 in early stage of acute pancreatitis
(Zhang et al., 2020), and revealed that the complement system can interact with cancer
cells to contribute to proliferation, migration, and invasion of tumor cells (Zhang et al.,
2019). C3 can be used as an effective marker for the diagnosis of PDAC at early stages
(Peterson et al., 2017). According to the RNA-seq data, C3 is significantly expressed at
higher level (1.5-fold) in KRASG12DEzh2SET compared to KRASG12D cells. Consistent with
these data, C3 was expressed in KRASG12DEzh2SET tissues in the mouse model that
received cerulein treatment five weeks before dissection. Positive C3 signals were
specifically observed in columnar epithelial cells within the lesion. Although it is still not
known if differentially expressed C3 contributes to the more progressive PanIN phenotype,
high C3 level is often correlated to inflammation in the body (Liu et a., 2016). Overall,
these data confirmed the finding that the absence of epigenetic repressor EZH2 results in
activation of expression of many genes including C3, and that inflammatory pathways
could be closely related to the development of early PDAC. As the RNA-seq analysis was
performed on tissue with a normal phenotype before progression to PanINs and without an
injury stimulant, I next investigated the possibility that KRASG12DEzh2SET mice show a
differential immune response to injury. Because the molecular response to KRAS activation
could be dramatically changed in response to injury, work on gene expression profiles at
later stages of PanIN progression is warranted in the future.
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4.5

EZH2 plays a role in tumor microenvironment modulation

Recent studies revealed an immune modulatory function of EZH2 in the TME (Wang et
al., 2019). To examine the immune response in the pancreas in the absence of EZH2 as
well as KRASG12D activation, I analyzed the effects of EZH2 knockout on accumulation of
immune cell populations and CAFs following acute pancreatic injury. KRASG12DEzh2SET
mice exhibited a trend towards decreased accumulation of T cells and cytotoxic T cells in
the TME compared to KRASG12D mice, and this could correspond to a more aggressive
phenotype of KRASG12DEzh2SET tissues. T cells are a type of leucocyte that plays an
important role in the body’s immune system. It is previously demonstrated that aberrant
EZH2 function plays a critical role in the recruitment of Tregs at the sites of inflammation,
which perform immunosuppressive functions by restricting the T effector cells (DuPage et
al., 2015; Yang et al., 2015). Overexpression of EZH2 in late-stage PDAC leads to
excessive recruitment of Tregs, which largely inhibits infiltration of cytotoxic cells and
therefore maintains a pro-tumor microenvironment. In this case, however, the deletion of
EZH2 results in a slightly restricted recruitment of cytotoxic T cells compared to tissues
with normal EZH2 function, suggesting distinct roles for EZH2 in the initiation and late
stage of PDAC. EZH2 is deleted specifically in acinar cells as the driver gene Mist1 is
acinar-specific, which may also explain the inconsistency between previous study and this
finding.
Surprisingly, I observed significantly more macrophages within the TME of KRASG12D
tissues. The amount of macrophage recruitment in the stroma largely varies in KRASG12D
samples from 0.20% to 2.25% positive stain verses the total lesion area, which may reflect
the variability seen previously for the percentages of lesions area in KRASG12D.
Macrophages are the most abundant immune cells in the TME and promote a favorable
microenvironment for cancer cells by directly interacting and inhibiting cytotoxic T cells
(Borrego et al., 1998). Therefore, the presence of macrophages is normally associated with
immunosuppression and poor clinical outcome which is inconsistent with KRASG12D
Ezh2SET tissue having fewer macrophages in the TME but exhibiting a more advanced
phenotype. Although it is hard to conclude the reason why this correlation appeared, it is
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possible that expression of EZH2 in KRASG12D tissues increases the inflammatory response
mediated by macrophages, which restrained the recruitment of CD3+ and CD8+ T cells to
the sites of inflammation in the TME. However, this thesis only focussed on early preneoplastic events when the PanIN lesions just started to appear with KRASG12D as the only
oncogenic mutation. This may explain the inconsistency since most previous studies
looked at late-stage PDAC with additional oncogenic mutations such as Tp53. In addition,
F4/80 is a global marker for macrophages, which includes anti-tumor inflammatory M1
subtype and tumorigenic immune-suppressive M2 subtype, making it hard to conclude
whether the massive infiltration of macrophages in KRASG12D tissues plays a role in
preventing or promoting PDAC.
The stromal response to pancreatic injury involves CAFs, which include myCAFs and
iCAFs. MyCAFs are believed to promote tumorigenesis by secreting soluble factors and
ECM proteins. In this study, however, no obvious differences were observed in the amount
of myCAFs and total CAFs in the TME in both genotypes, suggesting EZH2 deletion does
not enhance PDAC progression by altering CAFs in the TME. Combined, this data shows
Ezh2SET deletion in KRASG12D-mediated PanIN progression decreases immune infiltration
in pancreas but does not promote differences in CAFs remodeling.
In summary, EZH2’s role in preventing the progression of KRAS-driven PanIN lesions is
correlated with its function of epigenetically silencing immune-related genes and altering
associated inflammatory response pathways, which leads to higher level of immune cell
recruitment in the TME.

4.6

The role of EZH2 is context dependent

Next, I investigated whether the loss of Ezh2 in acinar cells caused more progressive KRASmediated ADM formation without the presence of surrounding TME. To do this, the effects
of EZH2 on the ADM process was assessed through primary acinar cultures. Oncogenic
KRASG12D activation and Ezh2 deletion were specifically induced in acinar cells 21 days
before acinar cell isolation and culturing in 3D collagen culture. Type I collagen was
specifically used for embedding acinar cells because collagen I is the most common type
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of ECM protein found in skin, bones, and connective tissues, and is suitable for maintaining
cells (Mochizuki et al., 2020). KRASG12D-expressing acinar cells, whether coupled with the
loss of EZH2 or not, showed increased acinar cell dedifferentiation and formed duct-like
cystic structures, suggesting a central role for KRASG12D in driving ADM, which is
consistent with previous study. Interestingly, the loss of EZH2 function did not result in a
greater percentage of KRAS-mediated ADM formation or significant increase in ADM size
in KRASG12D Ezh2SET cells as predicted. This suggests that the effects of EZH2 alone are
not able to cause visible phenotypic changes in acinar cells. Conversely, WT and Ezh2SET
cells exhibited a limited ability to form ADM in the culture, and acinar cell clusters are
short-lived. The size of cysts developed in WT and Ezh2SET were also considerably smaller
than that in KRASG12D and KRASG12DEzh2SET cultures. Similarly, the loss of EZH2 did not
seem to promote or prevent the formation of cysts without KRASG12D. It is noted that
following the first day in the culture, when KRASG12D-expressing cells rapidly underwent
ADM, the survival rate of cysts dropped quickly after day 2 in all genotypes, suggesting a
lack of the ability to proliferate. It is, however, expected because when these cells were
isolated and plated in the culture, they are normal acinar cells with WT-like phenotype, not
proliferating PDAC tumor cells that normally last longer in collagen culture. Overall, in
the absence of the TME, the loss of EZH2 did not results in more progressed ADM
formation even in the context of KRASG12D. This again suggests the role of EZH2 in
preventing PanIN progress in vivo might be context dependent. It is likely that the effects
of EZH2 in restricting PanIN progression is dependent on the TME.
However, it is possible that the deletion of EZH2 altered gene expression pattern in
KRASG12DEzh2SET cells but is not significant enough to lead to visible phenotypic changes
to the cysts. Further research is required to investigate whether the absence of EZH2
changes the molecular response of acinar cells to KRAS oncogene.

4.7

Limitations and future directions

In this study, limitations of both in vivo and in vitro experiments exist. In acute models of
PanIN, differences in collagen, myCAFs, and panCAFs in pancreatic tissues between
genotypes could not be assessed due to insufficient n value. To complete these analysis,
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repeated experiments with increased n values are needed. In terms of the in vitro work,
maintaining acinar cells in good condition over five experimental days provided limitations
to this study. In addition, technical difficulties in cysts isolation, fixation, and paraffinembedding following five days in culture limit the possibilities in histological analysis of
ADM.
In future studies, further efforts are required to establish the mechanisms by which EZH2
is restricting the progression of early PanIN lesions in the context of KRASG12D
hyperactivation. Performing ChIP-seq for H3K27me3 on acinar cells isolated at different
time points, for examples 21 days after tamoxifen injection or five weeks after cerulein
treatment, or five days after culturing, could be beneficial. This will allow us to determine
potential targets of EZH2 by looking at H3K27me3 pattern in the genome. It would also
help determine whether EZH2 has distinct roles in terms of the activation or silencing of
genes at different time points during early PanIN progression. To investigate the
involvement of EZH2 in intracellular mechanisms that restrict KRAS-mediated PanIN
progression, several significant genes could be chosen for expression analysis by
immunofluorescence (IF) or Western blotting to examine co-localization and amount of
expression in pancreatic tissues, which may help with identifying the involvement of these
genes in signaling pathways potentially affected by EZH2.
To further determine if the loss of EZH2 caused more progressive phenotype of ADM
through modulating the TME, cysts growth could be examined in culture under additional
conditions. Co-culture of mouse acinar cells and immune cells, including T cells and
macrophages, could be used to investigate individual role of immune cell recruitment
around ADM and whether KRAS-expressing cysts with EZH2 deletion will be more
proliferative and grow bigger. Alternatively, we could treat cells with chemicals released
by different immune cells, such as chemokines and cytokines, and monitor cyst growth to
see if the presence of any factors contributes to a more advance phenotype of ADM.
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4.8

Conclusion

In summary, the findings in this thesis support a preventive role for EZH2 in initiating
KRAS-driven PDAC. In the context of acute pancreatic injury in vivo, the loss of EZH2
leads to greater extent of preneoplastic PanIN lesions without limiting PanIN lesion
expansion. Although only a small number of genes are significantly dysregulated due to
the lack of EZH2 function in response to KRASG12D, most of them are upregulated in the
absence of EZH2 and are involved in multiple inflammatory response pathways, reflecting
the role of EZH2 as an epigenetic suppressor. I also identified the role of EZH2 in
modulating the tumor microenvironment by promoting recruitment of immune cells to the
sites of inflammation, which might in turn contribute to the less progressive outcome in
KRASG12D tissues. However, EZH2 is not able prevent KRAS-driven acinar cell
dedifferentiation in the cell culture, highlighting the context-dependent role of EZH2 in
repressing KRAS-mediated ADM and PanIN through modulating the TME.
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